# Chapter 105: Phencyclidine Intoxication

# The Biological and Neurological Basis of Phencyclidine Intoxication

## Introduction

Phencyclidine (PCP) is a dissociative anesthetic agent that has gained notoriety primarily through its illicit recreational use (Beede, 1980; Rastegar & Fingerhood, 2015). Originally synthesized for its anesthetic properties, its clinical application was curtailed due to the frequent emergence of severe psychiatric side effects, including agitation, delirium, and psychosis (Winters, 1976; Bey & Patel, 2007). The study of phencyclidine intoxication provides a unique window into the neurobiological underpinnings of consciousness, perception, and motor control. The clinical syndrome produced by PCP is remarkably complex and heterogeneous, combining stimulant, depressant, hallucinogenic, and analgesic effects (Mozayani, 2003). This multifaceted presentation creates a significant diagnostic challenge, as intoxication can mimic a wide range of primary psychiatric and neurological disorders, including acute psychosis, schizophrenia, status epilepticus, and traumatic head injury (Tong, 1975; Corales, 1980; Jacob et al., 1981).

The profound psychological disturbances induced by PCP have historically drawn comparisons to the schizophrenic state, making the drug a subject of intense interest as a pharmacological model for psychosis (Beede, 1980; Fauman et al., 1976). However, the neuropharmacological data are somewhat inconsistent with the classic dopaminergic hypothesis of schizophrenia, suggesting a more complex mechanism of action (Beede, 1980). Unlike classic psychedelic drugs such as lysergic acid diethylamide (LSD) or mescaline, the effects of PCP appear to be less dependent on the user's personality and more directly related to its pharmacological properties (SHOWALTER & Thornton, 1977). The intoxication state is highly dose-dependent, with clinical presentations ranging from mild agitation and disorientation to stupor, coma, and, in some cases, fatalities (Lerner et al., 1975; Milhorn, 1991).

This chapter will provide a comprehensive overview of the biological and neurological basis of phencyclidine intoxication, drawing exclusively from a defined body of research. It will explore the neuropharmacological mechanisms through which PCP exerts its effects, focusing on its interactions with key neurotransmitter systems. The discussion will cover the specific brain regions and neural circuits implicated in the diverse symptomatology of intoxication, from the motor disturbances of ataxia and dystonia to the perceptual distortions of hallucinations and the cognitive deficits of amnesia and thought disorder. Furthermore, this chapter will address the cellular and synaptic mechanisms underlying PCP's actions, the biological basis for the varied clinical subtypes of intoxication, and the neurological rationale for current treatment strategies. By synthesizing the available evidence, this chapter aims to construct a detailed, evidence-based model of the neurobiological cascade that defines phencyclidine intoxication.

## Neurobiological Systems

The clinical presentation of phencyclidine intoxication is remarkably diverse, reflecting the drug's broad impact across multiple neurotransmitter systems and neural circuits. Its effects are not confined to a single mechanism but rather emerge from a complex interplay of actions that disrupt glutamatergic, dopaminergic, serotonergic, and autonomic pathways. The unique combination of stimulant and depressant properties, along with profound dissociative and hallucinogenic effects, points to a widespread dysregulation of central nervous system (CNS) function (Mozayani, 2003; Bey & Patel, 2007).

### The Glutamatergic System and NMDA Receptor Antagonism

The primary and most well-characterized mechanism of action for phencyclidine and its congener, ketamine, is noncompetitive antagonism of the N-methyl-D-aspartate (NMDA) receptor, a key ionotropic receptor for the excitatory neurotransmitter glutamate (Andrade, 2017; Catts & Catts, 2010). This action is central to its classification as a "dissociative anesthetic" (Beede, 1980). By binding to a site within the NMDA receptor's ion channel, PCP blocks the influx of calcium ions, thereby preventing neuronal depolarization and inhibiting glutamatergic neurotransmission (Catts & Catts, 2010). This fundamental disruption of excitatory signaling is thought to underlie many of the hallmark features of PCP intoxication.

The profound sensory blockade, analgesia, and anesthesia reported in cases of intoxication are direct consequences of this NMDA receptor antagonism (Rainey & Crowder, 1975; Bey & Patel, 2007). The dissociative state itself, characterized by a feeling of detachment from one's body and environment, is a core feature shared with other NMDA antagonists like ketamine (Kalsi et al., 2011; Beede, 1980). Furthermore, the amnesia that is frequently observed, particularly the inability to recall the period of intoxication, is consistent with the critical role of NMDA receptors in learning and memory processes (Jacob et al., 1981; Rainey & Crowder, 1975; Jansen, 1990).

The psychotomimetic effects of PCP, which produce a syndrome that can be indistinguishable from schizophrenia, are also strongly linked to glutamatergic dysfunction (Catts & Catts, 2010; Fauman et al., 1976). The "glutamate hypothesis" of schizophrenia posits that hypofunction of NMDA receptors contributes to the positive, negative, and cognitive symptoms of the disorder (Meltzer, 2007). PCP and ketamine serve as powerful pharmacological models for schizophrenia precisely because their NMDA antagonism can induce a similar spectrum of symptoms in healthy individuals, including hallucinations, delusions, formal thought disorder, and social withdrawal (Catts & Catts, 2010; Beede, 1980). Dextromethorphan, another substance with PCP-like effects, also acts on the NMDA receptor system, further supporting this link (Logan et al., 2012). The neuronal hyperexcitability that can manifest as seizures in severe PCP intoxication may seem paradoxical for an NMDA antagonist but could result from the disinhibition of certain neuronal circuits, leading to uncontrolled electrical discharges (Winters, 1976; Tong, 1975; Lerner et al., 1975).

### The Dopaminergic System

While NMDA antagonism is the primary mechanism, the effects of PCP on the dopaminergic system are crucial for understanding its stimulant properties and its overlap with psychotic disorders. PCP has been shown to inhibit the reuptake and stimulate the release of dopamine, leading to increased synaptic dopamine levels (Mozayani, 2003; Mailman & Murthy, 2010). This action is shared with other psychostimulants like amphetamines and cocaine, which are also known to induce psychosis at high doses (Janowsky, 1973; Bell, 1973; Av, 1990). The resulting hyperdopaminergic state in mesolimbic and mesocortical pathways is believed to contribute significantly to the positive psychotic symptoms seen in PCP intoxication, such as paranoia, agitation, aggression, and delusions (Lerner & Burns, 1978; Bey & Patel, 2007; Fauman et al., 1976).

However, the relationship with the dopamine system is complex. Some neuropharmacologic data from the 1980s were considered inconsistent with a simple dopaminergic hypothesis of schizophrenia, suggesting that PCP's effects were not solely mediated by dopamine (Beede, 1980). This complexity is highlighted by the emergence of motor disturbances. Drug-induced movement disorders, such as acute dystonia (sustained muscle contractions), dyskinesias (involuntary movements), and parkinsonism, are classically associated with the blockade of dopamine D2 receptors in the nigrostriatal pathway by neuroleptic drugs (Tong, 1975; Montastruc et al., 1994; Duma & Fung, 2019). The occurrence of acute dystonic reactions, muscle rigidity, and opisthotonic posturing during PCP intoxication suggests a profound disruption of basal ganglia function, likely involving an imbalance of dopaminergic and cholinergic neurotransmission (Cogen, 1978; Jacob et al., 1981; Takahashi & Murasaki, 2005). This indicates that PCP does not simply increase dopamine transmission but creates a state of widespread dysregulation within motor circuits.

### The Serotonergic System

The hallucinogenic properties of PCP link it to the serotonergic system, the primary target of classic psychedelics like LSD, psilocybin, and mescaline (Cole & Katz, 1964; Snyder et al., 1969; Iversen et al., 2009). These drugs are known to be agonists at serotonin 5-HT2A receptors, which are crucial for their effects on perception and mood (Catts & Catts, 2010; Ghosh & Desousa, 2024). While PCP also produces altered perceptions, illusions, and hallucinations, its effects are considered unique and less dependent on individual personality compared to LSD (SHOWALTER & Thornton, 1977; Strassman, 1984). The visual, auditory, and tactile hallucinations reported during PCP intoxication suggest modulation of serotonergic pathways involved in sensory processing (Fauman et al., 1976; Mozayani, 2003). The interaction between PCP and serotonin systems may also contribute to mood changes, anxiety, and the development of prolonged depressive symptoms following intoxication (Lerner & Burns, 1978; Nijdam, 1990). The anxiogenic effects of PCP intoxication may share some pathways with other substances known to induce anxiety and panic attacks (Bradwejn & Koszycki, 1992; Ranganathan & Beitman, 1998).

### The Autonomic and Cholinergic Systems

Phencyclidine intoxication is characterized by significant autonomic hyperactivity, a direct consequence of its sympathomimetic effects (Mozayani, 2003). Hypertension and tachycardia are hallmark diagnostic signs and are consistently reported in clinical cases (Lerner et al., 1975; Nijam et al., 2018). These effects are likely mediated by the increased release of catecholamines such as norepinephrine, similar to other stimulants (Graddy & Rastegar, 2025). This sympathetic overstimulation can lead to serious cardiovascular complications, including arrhythmias and hypertensive emergencies, and contributes to the state of hyperthermia sometimes observed in severe cases (Lerner et al., 1975; Bey & Patel, 2007). Other autonomic signs include diaphoresis (profuse sweating) and excessive bronchial secretions (Jacob et al., 1981; Nijam et al., 2018).

While not a primary mechanism, PCP's interaction with the cholinergic system may contribute to its complex neuropsychiatric presentation. The delirium and confusion seen in PCP intoxication can share features with the central anticholinergic syndrome, which is characterized by disorientation, memory impairment, and hallucinations (Cook & Spence, 1997; Bellizzi et al., 2023). Some of the peripheral effects, such as mydriasis (dilated pupils) and urinary retention, can also be seen with anticholinergic agents (Barker & Solomon, 1990). Furthermore, the motor symptoms of dystonia and dyskinesia suggest an imbalance between dopaminergic and cholinergic systems in the basal ganglia, a mechanism well-established in movement disorders induced by neuroleptic drugs (Gelenberg, 1977; Duma & Fung, 2019). The presence of nystagmus (rapid, involuntary eye movements), a key diagnostic feature of PCP intoxication, points to a disruption of vestibulo-ocular pathways in the brainstem, which involves cholinergic neurotransmission (Lerner et al., 1975; Mozayani, 2003).

## Genetic and Molecular Basis

The biological basis of phencyclidine intoxication is profoundly influenced by factors at the genetic and molecular level, which dictate not only the drug's primary mechanism of action but also the marked heterogeneity in individual responses. While the provided literature does not contain specific genetic association studies for PCP, established principles of pharmacology and observations of clinical variability strongly suggest that genetic and molecular factors are critical determinants of susceptibility to both acute toxicity and long-term sequelae.

### Molecular Mechanisms of Action

At the molecular level, the defining action of PCP is its interaction with the NMDA receptor complex (Andrade, 2017; Catts & Catts, 2010). PCP acts as a noncompetitive antagonist by binding to a specific site located within the ion channel of the receptor, physically obstructing the flow of calcium ions (Catts & Catts, 2010). This "open-channel blockade" mechanism means that the receptor must first be activated by glutamate for PCP to gain access to its binding site. This activity-dependent blockade has profound implications, as it suggests PCP preferentially disrupts neuronal signaling in active, highly stimulated circuits. This could explain why its effects are so pronounced in cognitive and sensory processing pathways that rely heavily on glutamatergic transmission.

Beyond its primary target, PCP interacts with other molecular entities. It has been shown to bind to and inhibit the dopamine transporter (DAT), which is responsible for clearing dopamine from the synaptic cleft (Mozayani, 2003). This action, similar to that of cocaine, leads to an accumulation of synaptic dopamine and contributes to the drug's psychostimulant and psychosis-inducing effects (Janowsky, 1973; Bell, 1973). PCP also interacts with serotonin transporters and various serotonin receptor subtypes, although these interactions are less well-characterized than its effects on NMDA and dopamine systems (de la Torre et al., 2004; Catts & Catts, 2010). Furthermore, PCP has affinity for sigma-1 receptors, which are intracellular chaperone proteins that modulate a variety of signaling pathways, including calcium signaling and neurotransmitter release (Fernández, 2014). This interaction may contribute to its complex psychotomimetic and neuroplastic effects.

### Genetic Factors and Individual Vulnerability

The clinical observation that only a fraction of PCP users develop severe, prolonged psychosis suggests a significant role for individual vulnerability, which is likely rooted in genetic predisposition (Fauman et al., 1976). While no specific genes are identified in the source literature, several candidate systems can be hypothesized based on PCP's pharmacology.

First, genetic polymorphisms in the genes encoding subunits of the NMDA receptor could alter the receptor's structure or function, potentially affecting PCP's binding affinity or the downstream consequences of its blockade. Such variations might make certain individuals' glutamatergic systems more susceptible to disruption.

Second, variability in the dopaminergic system, such as polymorphisms in genes for the dopamine transporter (DAT) or dopamine receptors (e.g., D2), could influence the magnitude of the dopamine surge induced by PCP (Mailman & Murthy, 2010). Individuals with a genetic predisposition to hyperdopaminergic states, perhaps similar to those hypothesized for schizophrenia, might be at higher risk for experiencing psychotic symptoms during PCP intoxication (Citver et al., 2002; Goldberg, 1967).

Third, pharmacogenetic factors related to drug metabolism are almost certainly involved. The rate at which an individual metabolizes PCP can significantly affect the peak concentration and duration of the drug's effects, thereby influencing the severity of intoxication (Jacob et al., 1981). Although not studied for PCP in the provided papers, variations in cytochrome P450 (CYP) enzymes are known to cause significant differences in the metabolism of many psychotropic drugs, leading to interindividual differences in efficacy and toxicity (Shirata et al., 2023; Jansen, 2003). A "poor metabolizer" phenotype for the specific CYP enzymes involved in PCP breakdown could lead to prolonged exposure and a higher risk of severe or protracted toxic reactions.

Finally, a pre-existing genetic vulnerability to psychiatric disorders, such as schizophrenia or bipolar disorder, likely represents a major risk factor (Fauman et al., 1976; Mauri, 2016). PCP intoxication may act as a potent environmental trigger that unmasks or precipitates a latent psychosis in genetically susceptible individuals (Catts & Catts, 2010). The neurodevelopmental disruptions associated with these disorders might create a neural substrate that is particularly sensitive to the glutamatergic and dopaminergic dysregulation caused by PCP.

## Cellular and Synaptic Mechanisms

The profound behavioral and psychological effects of phencyclidine intoxication originate from its disruption of fundamental cellular and synaptic processes. By targeting key components of neuronal communication, PCP induces a cascade of events that alters synaptic plasticity, neuronal excitability, and ultimately, the integrity of neural circuits.

### Disruption of Synaptic Plasticity

The primary cellular mechanism of PCP is the blockade of NMDA receptors, which are critical for synaptic plasticity, particularly long-term potentiation (LTP), a cellular correlate of learning and memory (Andrade, 2017; Trujillo, 2002). By preventing the calcium influx necessary for LTP induction, PCP impairs the brain's ability to strengthen synaptic connections in response to experience (Meneses, 2013). This disruption of synaptic plasticity in regions like the hippocampus and cerebral cortex provides a direct cellular basis for the profound amnesia and cognitive deficits observed during intoxication (Jacob et al., 1981; Jansen, 1990). The inability to form new memories and the frequent amnesia for the entire intoxicated period are clinical manifestations of this synaptic failure (Rainey & Crowder, 1975). This mechanism is shared with ketamine, which has also been studied for its effects on memory and cognition (Jansen, 1990; Andrade, 2017).

### Alteration of Neuronal Excitability and Seizures

PCP's effects on neuronal excitability are complex and seemingly paradoxical. While its primary action is to block an excitatory receptor, severe intoxication can lead to neuronal hyperexcitability manifesting as myoclonus, convulsions, and status epilepticus (Tong, 1975; Lerner et al., 1975; Winters, 1976). This phenomenon is likely due to the disinhibition of specific neural circuits. NMDA receptors are present on both excitatory (pyramidal) neurons and inhibitory (GABAergic) interneurons. It is hypothesized that PCP may preferentially block NMDA receptors on inhibitory interneurons, thereby reducing GABAergic tone and releasing pyramidal cells from their normal inhibitory control (Faingold & Riaz, 2019). This leads to a state of cortical hyperexcitability and uncontrolled, synchronous neuronal firing, which is the cellular basis of a seizure (Browne & Penry, 1973). This mechanism highlights how disrupting the delicate balance between excitation and inhibition can lead to pathological network activity (Kofke et al., 1997).

### Neurotransmitter Dysregulation at the Synapse

At the synaptic level, PCP intoxication is characterized by widespread neurotransmitter dysregulation. In addition to blocking postsynaptic NMDA receptors, PCP also inhibits the presynaptic reuptake of dopamine and, to a lesser extent, norepinephrine and serotonin (Mozayani, 2003; Mailman & Murthy, 2010). This leads to an accumulation of these monoamines in the synaptic cleft, prolonging their action on postsynaptic receptors. The increased dopaminergic transmission in mesolimbic pathways is thought to be a key synaptic event underlying the drug's reinforcing properties and the development of psychotic symptoms such as paranoia and delusions (Janowsky, 1973; Bell, 1973). The simultaneous increase in norepinephrine contributes to the sympathomimetic effects of hypertension and tachycardia (Lerner et al., 1975). The modulation of serotonin release and reuptake likely contributes to the hallucinogenic and perceptual-distorting effects of the drug (de la Torre et al., 2004; Catts & Catts, 2010). This complex pattern of monoamine dysregulation, superimposed on a background of glutamatergic blockade, creates a unique and chaotic synaptic environment that drives the diverse clinical presentation.

### Neurotoxicity and Cellular Damage

Prolonged or high-dose exposure to PCP raises concerns about potential neurotoxicity and lasting cellular damage (Yoshimura & Imai, 1990). The state of neuronal hyperexcitability during PCP-induced seizures can lead to excitotoxicity, a process where excessive glutamate release and receptor activation cause a massive influx of calcium, triggering apoptotic and necrotic cell death pathways (Faingold & Riaz, 2019). This mechanism is a known contributor to neuronal injury in status epilepticus from other causes (Cavalheiro et al., 1991).

Furthermore, the extreme metabolic and physiological stress associated with severe PCP intoxication, including hyperthermia, rhabdomyolysis, and hypoxia from respiratory depression, can independently cause cellular damage throughout the body, including the brain (Reddy & Kornblum, 1987; Cogen, 1978; Jacob et al., 1981). Rhabdomyolysis, the breakdown of skeletal muscle, releases myoglobin into the circulation, which can lead to acute renal failure, further contributing to a toxic metabolic state (Cogen, 1978). While the provided literature does not contain direct histopathological evidence of PCP-induced neuronal death in humans, the presence of these severe systemic complications, combined with the known mechanisms of excitotoxicity, suggests that lasting cellular damage is a plausible consequence of severe intoxication (Yoshimura & Imai, 1990). The chronic cognitive deficits, thinking disorders, and personality changes reported in some long-term users may reflect the cumulative result of these neurotoxic insults (Lerner & Burns, 1978).

## Brain Structure and Function

Phencyclidine intoxication induces a global disruption of brain function, manifesting as a complex syndrome of motor, sensory, cognitive, and psychiatric disturbances. Although the available literature lacks modern neuroimaging studies such as functional magnetic resonance imaging (fMRI) or positron emission tomography (PET) to directly visualize PCP's effects on the human brain, a clear understanding of the implicated brain regions can be inferred by correlating the drug's well-documented clinical signs and symptoms with the known functions of specific neural structures and circuits.

### Cerebral Cortex: The Seat of Psychosis and Cognitive Disruption

The most dramatic effects of PCP intoxication—psychosis, thought disorder, amnesia, and perceptual disturbances—point to widespread dysfunction of the cerebral cortex, particularly the frontal and temporal lobes (Fauman et al., 1976; Lerner & Burns, 1978). The psychosis induced by PCP can be indistinguishable from schizophrenia, featuring paranoid delusions, auditory and visual hallucinations, and disorganized thought and speech (Jacob et al., 1981; Rainey & Crowder, 1975). This clinical parallel suggests a disruption of the same frontotemporal circuits implicated in primary psychotic disorders, which are responsible for reality testing, executive function, and language processing (Catts & Catts, 2010; Dodd, 2007). The profound amnesia for the period of intoxication, a hallmark feature, strongly implicates the hippocampus and other medial temporal lobe structures essential for memory formation (Jacob et al., 1981; Jansen, 1990). The experience of depersonalization and derealization, or a feeling of detachment from oneself and reality, also suggests altered processing within cortical association areas responsible for integrating sensory information and generating a cohesive sense of self (Linton, 1962; Snyder et al., 1969).

### Basal Ganglia: The Origin of Motor Disturbances

The prominent motor abnormalities seen in PCP intoxication are indicative of severe dysregulation within the basal ganglia, the set of subcortical nuclei crucial for motor control (Takahashi & Murasaki, 2005; Fahn et al., 2003). Clinical reports frequently describe acute dystonic reactions (sustained, abnormal postures), dyskinesias (abnormal involuntary movements), muscle rigidity, and choreoathetoid movements (Tong, 1975; Cogen, 1978; Mozayani, 2003). These symptoms mirror those seen in drug-induced movement disorders caused by dopamine-blocking neuroleptic agents, which directly target D2 receptors in the striatum (a key component of the basal ganglia) (Montastruc et al., 1994; Duma & Fung, 2019). The bizarre posturing, such as opisthotonus (severe arching of the back), and facial grimacing are classic signs of extrapyramidal dysfunction (Jacob et al., 1981). The presence of these motor symptoms demonstrates that PCP profoundly disrupts the delicate balance of neurotransmitter activity, particularly dopamine and acetylcholine, within the nigrostriatal pathway that governs voluntary movement (Gelenberg, 1977).

### Cerebellum and Brainstem: Mediators of Ataxia, Nystagmus, and Autonomic Instability

Several key diagnostic signs of PCP intoxication point directly to dysfunction of the cerebellum and brainstem. Ataxia, characterized by an uncoordinated, unsteady gait, is a common finding and reflects impairment of the cerebellum's role in coordinating movement and balance (Jacob et al., 1981; Mozayani, 2003; Nauth-Misir, 1948). Dysarthria, or slurred speech, also results from cerebellar and brainstem disruption of motor speech control (Mozayani, 2003).

Perhaps the most specific clinical sign of PCP intoxication is nystagmus, which can be horizontal, vertical, or rotatory (Lerner et al., 1975). The presence of vertical nystagmus is particularly suggestive of PCP use (Lerner et al., 1975). These involuntary eye movements are generated by disturbances in the vestibulo-ocular pathways within the brainstem, which are responsible for stabilizing gaze during head movement (Esser & Brandt, 1983).

The brainstem also houses the vital autonomic control centers. PCP's powerful sympathomimetic effects, leading to hypertension and tachycardia, are mediated through these brainstem nuclei, which regulate cardiovascular function (Lerner et al., 1975; Nijam et al., 2018). Furthermore, the level of consciousness is controlled by the reticular activating system in the brainstem. The progression from agitation to stupor and coma in high-dose intoxications reflects a dose-dependent depression of this arousal system (Tong, 1975; Lerner et al., 1975; Bey & Patel, 2007). Respiratory depression, which can be life-threatening, is also a direct result of PCP's action on medullary respiratory centers (Jacob et al., 1981).

### Thalamus and Sensory Pathways

The thalamus acts as a central relay station for nearly all sensory information ascending to the cortex. PCP's function as a dissociative anesthetic involves a profound blockade of sensory information processing (Corales, 1980). This "sensory blockade" is responsible for the powerful analgesic and anesthetic effects of the drug (Rainey & Crowder, 1975). By disrupting glutamatergic transmission within thalamocortical circuits, PCP effectively disconnects the cortex from incoming sensory input, leading to an altered state of consciousness where pain is not perceived and external stimuli are not processed normally. This functional deafferentation contributes to the disorientation, confusion, and hallucinatory experiences of the intoxicated state (SHOWALTER & Thornton, 1977).

## Developmental Neurobiology

The impact of phencyclidine on the brain is not uniform across the lifespan; rather, its effects are significantly modulated by the developmental stage of the central nervous system. Epidemiological data consistently indicate that PCP abuse is most prevalent among adolescents and young adults, a period of dynamic neurodevelopmental change (Lerner & Burns, 1978; Rastegar & Fingerhood, 2015). This raises critical questions about the unique vulnerability of the developing brain to the neurobiological insults posed by PCP. While the provided literature does not contain longitudinal studies specifically tracking the developmental effects of PCP, principles of developmental neurobiology and evidence from related fields allow for an informed discussion of these risks.

### The Adolescent Brain as a Vulnerable Substrate

Adolescence is a critical period characterized by significant remodeling of key neural circuits, particularly those involving the prefrontal cortex and the limbic system (Ingram, 1956). These regions are essential for executive functions, impulse control, emotional regulation, and social cognition—the very functions that are profoundly disrupted during PCP intoxication (Lerner & Burns, 1978; Fauman et al., 1976). The neurochemical systems underlying this maturation, especially the glutamatergic and dopaminergic systems, are the primary targets of PCP (Catts & Catts, 2010; Mailman & Murthy, 2010).

The adolescent brain exhibits a state of heightened synaptic plasticity, which is necessary for learning and adaptation but also renders it more susceptible to environmental insults, including drug exposure (Dubovický, 2010). The introduction of a potent NMDA receptor antagonist like PCP during this sensitive window could interfere with normal synaptic pruning and circuit refinement processes. By disrupting activity-dependent plasticity, chronic PCP use during adolescence could theoretically lead to lasting alterations in cortical connectivity, potentially predisposing individuals to long-term cognitive deficits or an increased risk for psychiatric disorders later in life (Lerner & Burns, 1978).

The increased prevalence of risk-taking and novelty-seeking behaviors in adolescence may also contribute to the patterns of PCP use (Lerner & Burns, 1978). The developing prefrontal cortex has a diminished capacity for impulse control compared to the adult brain, making adolescents more likely to engage in substance use (Pickard, 2011). Furthermore, the dopaminergic reward system is particularly robust during this period, which may enhance the reinforcing effects of drugs like PCP that increase dopamine levels, thereby facilitating the transition from experimental use to abuse and dependence (Kollins, 2003).

### Potential for Long-Term Psychiatric Sequelae

The use of PCP during youth is associated with a range of troubling outcomes, including thinking disorders, personality changes, paranoia, and severe depression that can persist beyond the period of acute intoxication (Lerner & Burns, 1978). While it is difficult to disentangle the causal relationship from pre-existing vulnerabilities, it is plausible that PCP exposure during a critical neurodevelopmental period could contribute to the pathogenesis of these chronic conditions. The PCP model of schizophrenia is built on the observation that the drug can induce a state that closely mimics the primary illness (Beede, 1980; Catts & Catts, 2010). Exposure during adolescence, when the brain is finalizing the circuits that are thought to be dysfunctional in schizophrenia, could represent a "second hit" that, in genetically vulnerable individuals, triggers the onset of a lifelong psychotic illness (Dodd, 2007).

### Considerations in Pediatric and Neonatal Populations

While less documented, the potential effects of PCP on even younger developmental stages are of significant concern. In utero exposure to psychoactive substances can have devastating consequences for fetal brain development (Gordon, 1979). Maternal drug use can lead to a neonatal withdrawal syndrome characterized by irritability, tremors, sleep disturbances, and feeding difficulties (Blatman, 1974; Amato et al., 1982). Although specific data on PCP are sparse in the provided literature, the general principles of neonatal drug withdrawal would apply, with the infant experiencing a state of CNS hyperexcitability following the abrupt cessation of in utero drug exposure (Serrano, 2019). The long-term neurobehavioral consequences of such exposure are poorly understood but could include an increased risk for developmental delays, attentional problems, and behavioral disorders (Ingram, 1956; Millichap, 1968). The diagnosis of behavioral disorders in children is complex, and a history of prenatal substance exposure should be considered as a potential contributing factor (Liegl & Martinius, 1991).

## Treatment Mechanisms

The management of phencyclidine intoxication is primarily supportive and symptomatic, as there is no specific pharmacological antidote to reverse its effects (Tong, 1975; Lerner et al., 1975). The therapeutic strategies employed are grounded in an understanding of the drug's neurobiological actions and are aimed at mitigating its life-threatening complications, controlling severe behavioral disturbances, and facilitating its elimination from the body.

### Environmental and Supportive Management

A cornerstone of managing PCP intoxication is the reduction of sensory stimulation (Tong, 1975). Patients are often hypersensitive to external stimuli, which can exacerbate agitation, paranoia, and psychosis (SHOWALTER & Thornton, 1977). Therefore, placing the patient in a quiet, dimly lit environment with minimal interaction—a practice often termed "sensory isolation"—is a critical first-line intervention (Lerner et al., 1975). This approach contrasts with the "talking down" techniques used for classic hallucinogen intoxication, which can be counterproductive and even dangerous for a PCP-intoxicated individual (SHOWALTER & Thornton, 1977).

In cases of severe intoxication leading to stupor or coma, the primary focus is on life support (Milhorn, 1991). This involves vigilant monitoring and maintenance of the airway, breathing, and circulation (ABC), as respiratory depression and cardiovascular collapse are potential fatal complications (Jacob et al., 1981; Bey & Patel, 2007). Protection of the airway is paramount, especially given the risk of vomiting and aspiration in an unresponsive patient (Wall et al., 2006).

### Pharmacological Control of Agitation and Seizures

For severe agitation, violence, or seizure activity, pharmacological intervention is necessary (Lerner et al., 1975). Benzodiazepines, particularly diazepam, are the agents of choice for managing these CNS hyperexcitability states (SHOWALTER & Thornton, 1977). The neurobiological rationale for their use lies in their mechanism as positive allosteric modulators of the GABA-A receptor (Browne & Penry, 1973). By enhancing the effects of the brain's primary inhibitory neurotransmitter, GABA, benzodiazepines can counteract the neuronal hyperexcitability induced by PCP's glutamatergic and dopaminergic actions, thereby raising the seizure threshold and producing sedation (Kofke et al., 1997; Nelson & Chouinard, 1999). Their use is a targeted intervention to restore inhibitory tone in a CNS that has become dangerously disinhibited (Harangozó et al., 1991).

While neuroleptic (antipsychotic) drugs are effective for managing psychosis and agitation in other contexts, their use in acute PCP intoxication is approached with caution (Marder, 2006). The dopamine-blocking action of traditional antipsychotics could theoretically worsen the dystonic reactions and other extrapyramidal symptoms sometimes seen with PCP, and their anticholinergic properties could exacerbate delirium (Keckich, 1978; Bellizzi et al., 2023). However, in cases of prolonged psychosis that persist after the acute intoxication phase has resolved, antipsychotic medications may be required (Rainey & Crowder, 1975; Fauman et al., 1976).

### Enhancing Drug Elimination

A specific pharmacokinetic strategy to manage PCP intoxication is the acidification of the urine (Beede, 1980). Phencyclidine is a weak base. By lowering the pH of the urine (e.g., with ammonium chloride or ascorbic acid), a greater proportion of the drug becomes ionized. This "ion trapping" prevents its reabsorption from the renal tubules back into the bloodstream, thereby accelerating its excretion from the body (Beede, 1980). This intervention directly targets the drug's elimination pathway to reduce the duration of toxic exposure. However, this procedure carries risks, particularly in patients with rhabdomyolysis, as acidification of the urine can promote the precipitation of myoglobin in the renal tubules and worsen acute kidney injury (Cogen, 1978). Therefore, its use must be carefully considered based on the patient's overall clinical status.

### Treatment of Refractory Psychosis

In a subset of individuals, PCP intoxication can trigger a severe, prolonged schizophreniform psychosis that is resistant to standard pharmacological treatments (Rainey & Crowder, 1975; Fauman et al., 1976). In such refractory cases, electroconvulsive therapy (ECT) has been reported to be an effective intervention (Grover et al., 1986). The precise neurobiological mechanism of ECT is not fully understood, but it is known to induce widespread neurochemical changes, including modulation of dopamine, serotonin, and GABA systems, and to have potent anticonvulsant effects (Alexander, 1953; Kaliora, 2021). It is hypothesized that the generalized seizure induced by ECT acts as a "reset" for the dysregulated neural circuits underlying the persistent psychosis, restoring a more normal state of brain function (Grover et al., 1986). The effectiveness of ECT in this context highlights the severity of the neurobiological disruption that PCP can induce and points to the involvement of fundamental mechanisms of neuronal excitability and network function.

## Future Directions

Despite decades of clinical observation and preclinical research, our understanding of the biological and neurological basis of phencyclidine intoxication remains incomplete. The existing literature, while providing a solid foundation based on clinical phenomenology, reveals significant gaps that represent critical avenues for future investigation. The advent of modern neuroscientific tools offers an unprecedented opportunity to elucidate the complex mechanisms underlying PCP's effects and to develop more targeted and effective interventions.

A primary and pressing need is for neuroimaging research in humans. The current understanding of which brain structures and networks are affected by PCP is largely inferred from clinical symptoms (Corales, 1980; Jacob et al., 1981). The application of functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) could directly visualize the acute effects of PCP or its analogs (like ketamine) on brain activity, functional connectivity, and receptor occupancy. Such studies would allow for the precise mapping of the neural circuits involved in the dissociative state, psychosis, and motor disturbances, moving beyond the current correlational understanding (Kerchner & Rosenbloom, 2014). For instance, imaging could clarify the relative contributions of cortical, subcortical, and cerebellar regions to the ataxic and dyskinetic symptoms of intoxication (Takahashi & Murasaki, 2005).

On a molecular level, the full spectrum of PCP's receptor interactions is not yet known. While its action as an NMDA receptor antagonist is well-established (Catts & Catts, 2010), the roles of its interactions with dopamine transporters, various serotonin receptor subtypes, sigma receptors, and cholinergic systems require deeper investigation (Mailman & Murthy, 2010; de la Torre et al., 2004). Future research should aim to characterize the binding affinities and functional consequences of these interactions to build a more comprehensive pharmacological profile. This knowledge is essential for understanding the drug's heterogeneous effects and for the rational design of potential antidotes or modulators.

The marked interindividual variability in response to PCP, particularly the development of prolonged psychosis in a subset of users, points to the importance of genetic factors (Fauman et al., 1976). Future genetic association studies are needed to identify specific polymorphisms—in genes related to NMDA receptors, dopamine or serotonin signaling, or drug metabolism—that confer susceptibility or resilience to PCP's adverse psychiatric effects. Identifying these genetic risk factors could enable personalized risk assessment and might shed light on the shared genetic architecture between drug-induced psychosis and primary psychotic disorders like schizophrenia (Mauri, 2016).

Longitudinal studies are crucial to understand the long-term neurobiological consequences of chronic PCP use. Reports of persistent memory loss, thinking disorders, and personality changes suggest the potential for lasting neurotoxicity, but the structural and functional basis for these deficits is unknown (Lerner & Burns, 1978). Prospective studies combining neuroimaging and comprehensive neuropsychological testing in chronic users could document changes in brain structure (e.g., cortical thickness, white matter integrity) and function over time, clarifying whether PCP causes irreversible neuronal damage (Yoshimura & Imai, 1990).

Finally, the development of targeted therapeutic interventions remains a major goal. Currently, management is entirely supportive (Tong, 1975; Lerner et al., 1975). Research into specific pharmacological antagonists that can reverse or mitigate the effects of PCP at the NMDA receptor or other key targets could lead to the first specific antidote for PCP overdose. Furthermore, a better understanding of the mechanisms underlying PCP-induced psychosis could inform the development of more effective treatments for this severe and often refractory condition, potentially leveraging novel targets beyond the dopamine D2 receptor (Grover et al., 1986; Meltzer, 2007). The continued study of PCP and its analogs not only holds promise for improving the care of intoxicated patients but also continues to offer a valuable pharmacological tool for probing the fundamental neurobiology of psychosis, consciousness, and memory.

## Conclusion

Phencyclidine intoxication presents a profound and multifaceted challenge to the central nervous system, resulting in a clinical syndrome of remarkable complexity and severity. The biological underpinnings of this state are rooted in the drug's primary action as a noncompetitive antagonist of the NMDA glutamate receptor, a mechanism that fundamentally disrupts the brain's main excitatory neurotransmitter system (Andrade, 2017; Catts & Catts, 2010). This glutamatergic blockade is the cornerstone of PCP's dissociative, anesthetic, and amnestic properties, effectively disconnecting cortical processing from sensory input and disrupting the cellular basis of memory formation (Rainey & Crowder, 1975; Jacob et al., 1981).

However, the neurobiology of PCP intoxication extends far beyond a single receptor system. The drug's concurrent modulation of dopaminergic and serotonergic pathways contributes significantly to its psychotomimetic, hallucinogenic, and stimulant effects, producing a state that can be clinically indistinguishable from acute schizophrenia (Beede, 1980; Fauman et al., 1976). This dual disruption of glutamate and monoamine systems creates a state of profound neural dysregulation, affecting a constellation of brain regions, including the prefrontal cortex, temporal lobes, basal ganglia, and brainstem. The resulting clinical picture is a dose-dependent spectrum of symptoms, from agitation, ataxia, and nystagmus at lower doses to stupor, coma, seizures, and life-threatening autonomic instability at higher doses (Lerner et al., 1975; Milhorn, 1991).

The motor disturbances, including acute dystonias and rigidity, highlight the drug's impact on the extrapyramidal system, while autonomic signs such as hypertension and tachycardia reflect its potent sympathomimetic activity (Tong, 1975; Lerner et al., 1975). The variability in individual responses, particularly the precipitation of prolonged psychosis in vulnerable individuals, underscores the likely role of underlying genetic and neurodevelopmental factors, though these remain poorly defined (Fauman et al., 1976; Lerner & Burns, 1978).

Management of PCP intoxication remains a process of supportive care, focused on mitigating environmental stimuli and treating emergent complications such as seizures and hyperthermia, as no specific antidote exists (SHOWALTER & Thornton, 1977). The study of phencyclidine has not only been critical for understanding and treating a specific form of drug toxicity but has also provided an invaluable, albeit challenging, pharmacological model. It has been instrumental in advancing the glutamate hypothesis of schizophrenia and continues to offer insights into the fundamental neurobiological mechanisms that govern perception, cognition, and consciousness. Acknowledging the significant gaps that remain in our knowledge, particularly regarding long-term neurotoxicity and genetic risk factors, is essential for guiding future research toward a more complete understanding of this unique and powerful psychoactive agent.

## References

1. Abanoz, Y. G., Abanoz, Y., Gündüz, A., Uzun, N., & Kızıltan, M. E. (2016). Clinical and Electrophysiological Findings in Two Siblings with Familial Hyperekplexia. Nöro Psikiyatri Arşivi. https://doi.org/10.5152/npa.2016.11314
2. Abhilash, K. P., Jha, A., Bandhyopadhyay, R., & Victor, P. (2014). Hypoglycemia - A rare complication of carbamazepine overdose. Indian Journal of Pharmacology. https://doi.org/10.4103/0253-7613.144941
3. Adi, Y., Ashcroft, D. M., Browne, K. D., Beech, A. R., Fry-Smith, A., & Hyde, C. (2002). Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technology Assessment. https://doi.org/10.3310/hta6280
4. Aggarwal, M., & Sindhu, B. (2016). Hallucinations and dyskinesia with pramipexole in parkinson's disease-a case report. International Journal of Basic & Clinical Pharmacology. https://doi.org/10.18203/2319-2003.ijbcp20163275
5. Agrawal, M., Borkar, S., & Kale, S. S. (2019). Phenytoin toxicity manifesting as acute psychosis: An uncommon side effect of a common drug. Asian Journal of Neurosurgery. https://doi.org/10.4103/ajns.ajns_86_18
6. Ahlskog, J. E., & Wilkinson, J. M. (1990). New concepts in the treatment of Parkinson's disease.. PubMed.
7. Ahn, Y. J., Jeong, Y. G., Lim, M. H., Bae, I. G., Kim, S. J., Kang, H. Y., & Heo, S. T. (2009). A case of Cefepime-induced encephalopathy in a patient with chronic kidney failure. The Korean Journal of Internal Medicine.
8. Akbuga-Ozel, B., Aksel, G., Kilicli, E., Muratoğlu, M., Kavalcı, C., Gülalp, B., & Kayıpmaz, A. E. (2017). Metoclopramide-induced acute dystonic reaction misinterpreted as conversion disorder and seizure. Electronic Journal of General Medicine. https://doi.org/10.29333/ejgm/81746
9. Albishri, S. B., Alotaibi, A. B., Alzoubaidi, F. M., & Elserafy, O. S. (2023). Flakka: “The Zombie Drug” A Medicolegal Concern: An Updated Review of α-Pyrrolidinopentiophenone. The Saudi Journal of Forensic Medicine and Sciences. https://doi.org/10.4103/sjfms.sjfms_7_23
10. Albright, P. S., & Bruni, J. (1984). Pharmacokinetic Interactions of Antiepileptic Drugs. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/s0317167100045480
11. Alexander, L. (1953). THE EFFECT OF ELECTROSHOCK ON A "NORMAL" PERSON UNDER RECENT STRESS. American Journal of Psychiatry. https://doi.org/10.1176/ajp.109.9.696
12. Altun, H., Gül, Ö., Öksüz, A. N., & Şahın, N. (2017). Cyclic vomiting syndrome treated successfully with fluoxetin. Türk Pediatri Arşivi. https://doi.org/10.5152/tpa.2014.1373
13. Amato, M., Frei, H., & Buhlmann, U. (1982). [Drug withdrawal syndrome in the neonate].. PubMed.
14. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
15. Anderson, M. (2010). Benzodiazepines for prolonged seizures. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/adc.2009.176321
16. Andrade, C. (2017). Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17f11567
17. Angelis, M. V. D., Giacomo, R. D., Muzio, A. D., Onofrj, M., & Bonanni, L. (2016). A subtle mimicker in emergency department. Medicine. https://doi.org/10.1097/md.0000000000005137
18. Anshel, M. H. (2016). Coping with stress in law enforcement. Routledge eBooks. https://doi.org/10.4324/9781315611075-14
19. Appenzeller, O., & Atkinson, R. E. (1975). [Transcutaneous nerve stimulation for the treatment of migraine and other head pain (author's transl)].. PubMed.
20. Araújo, F. M., & DeSantana, J. M. (2019). Physical therapy modalities for treating fibromyalgia. F1000Research. https://doi.org/10.12688/f1000research.17176.1
21. Armstrong, C. (2010). AAN Recommendations on Symptomatic Treatment for Muscle Cramps. American family physician.
22. Arora, M., Boruah, D. K., Thakker, V., & Bhanwra, S. (2021). ‘Phenytoin: Shepherd or Wolf in Disguise? Phenytoin-Induced Neurotoxicity: A Case Series. Neurology India. https://doi.org/10.4103/0028-3886.323888
23. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
24. Assareh, M., & Habibi, L. K. (2010). Afebrile Neuroleptic Malignant Syndrome associated with Fluphenazine decanoate: A case report.. PubMed.
25. Av, S. (1990). [Psychomotor stimulants as agents for enhancing work capacity].. PubMed.
26. Ayşe, H., Hakkı, ©., Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium?. Gazi Medical Journal. https://doi.org/10.12996/gmj.2017.45
27. Babington, M. A., & Monson, R. A. (1982). Dependence on Midol.. PubMed.
28. Banerjee, R., Ghosh, A. K., Ghosh, B., & Mondal, A. C. (2011). Stress: The Negative Modulator of NGF. Journal of Life Sciences.
29. Bansode, M. T., Chaware, V. J., & Redasani, V. K. (2021). Evaluation of anticataleptic activity of Hydroxytyrosol on Haloperidol induced Catalepsy in Experimental Animal. Asian Journal of Pharmaceutical Research and Development. https://doi.org/10.22270/ajprd.v9i4.990
30. Baquero, M. A., Arbeloa, M. C., Lugea, A. E., Urarte, M. N., & Carricas, M. S. (2023). 5PSQ-051 Parkinsonism induced by taking trazodone as a hypnotic: a case report. Section 5: Patient safety and quality assurance. https://doi.org/10.1136/ejhpharm-2023-eahp.269
31. Barnes, T. R. E., & McPhillips, M. A. (1998). Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199803003-00009
32. Barnovitz, M. A. L. C. M., & Joglekar, P. M. (2007). Medical Psychiatry: The Quick Reference.
33. Baronia, R. B. (2015). Oral Hydrocodone Induced Acute Psychosis in an Adult Male: A CaseReport.. Journal of Clinical Case Reports. https://doi.org/10.4172/2165-7920.1000535
34. Barrera, M. N. (1999). Mioclonías y Epilepsias Mioclónicas en la infancia. Revista de Neurología. https://doi.org/10.33588/rn.2803.98387
35. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
36. Basavilvazo-Rodríguez, A., Bravo-Rodríguez, L. M., Carranza‐Lira, S., Celis-González, C., Marín, I. H., Hernández-Valencia, M., Navarro, M. E. L., Maldonado, J. D. D. A., Montaño, J., Avellán, A. J. M., & Vázquez, G. G. (2012). [Consensus conference of the Mexican Association for the Study of Climateric on veralipride prescription for patients with vasomotor symptoms].. PubMed.
37. Bašić-Kes, V., Zavoreo, I., Bosnar-Puretić, M., Ivanković, M., Bitunjac, M., Govori, V., & Demarin, V. (2009). Neuropathic pain.. PubMed.
38. Beed, M., Sherman, R. A., & Mahajan, R. (2013). Neurology. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696277.003.0005
39. Beede, M. S. (1980). Phencyclidine intoxication. Postgraduate Medicine. https://doi.org/10.1080/00325481.1980.11715603
40. Bell, D. S. (1973). The Experimental Reproduction of Amphetamine Psychosis. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1973.04200010020003
41. Bellizzi, A., Mercieca, E., & Dimech, C. (2023). Delirium secondary to anticholinergics. BMJ Case Reports. https://doi.org/10.1136/bcr-2022-253547
42. Bengtsson, B.-O. (1992). On the hypersensitivity syndrome induced by the selective serotonin reuptake inhibiting antidepressant Zimeldine : A clinical and experimental study.
43. Berger, M., & Sachs, A. (1953). PERCEPTIVE DEAFNESS ASSOCIATED WITH PROPHYLACTIC USE OF TETANUS ANTITOXIN. Archives of Otolaryngology - Head and Neck Surgery. https://doi.org/10.1001/archotol.1953.00710030524003
44. Berry‐Kravis, E., Abrams, L., Coffey, S. M., Hall, D. A., Greco, C., Gane, L. W., Grigsby, J., Bourgeois, J. A., Finucane, B., Jacquemont, S., Brunberg, J. A., Zhang, L., Lin, J., Tassone, F., Hagerman, P. J., Hagerman, R. J., & Leehey, M. A. (2007). Fragile X‐associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. Movement Disorders. https://doi.org/10.1002/mds.21493
45. Bey, T., & Patel, A. (2007). Phencyclidine Intoxication andAdverse Effects: A Clinical and PharmacologicalReview of an Illicit Drug.
46. Bhutani, M., Colucci, P., Laird‐Fick, H., & Conley, B. A. (2011). Management of paclitaxel-induced neurotoxicity. Oncology Reviews. https://doi.org/10.4081/oncol.2010.107
47. Bismuth, C., Bellec, L., Dally, S., & Lagier, G. (1980). [Benzodiazepine physical dependence. 6 cases (author's transl)].. PubMed.
48. Bithal, P. K., & Chavali, S. (2021). Paroxysmal Sympathetic Hyperactivity: Ignoring the Presence of an Elephant in the Room. Journal of Neuroanaesthesiology and Critical Care. https://doi.org/10.1055/s-0041-1740206
49. Blatman, S. (1974). Narcotic Poisoning of Children (1) Through Accidental Ingestion of Methadone and (2) <i>in utero</i>. PEDIATRICS. https://doi.org/10.1542/peds.54.3.329
50. Bostwick, J. R., & Demehri, A. (2017). Pills to Powder: An Updated Clinician's Reference for Crushable Psychotropics. Current psychiatry.
51. Bradwejn, J., & Koszycki, D. (1992). CCK receptors and panic attacks in man. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198577560.003.0011
52. Brandt, T., & Esser, J. (1983). Pharmakologisch verursachte Augenbewegungsstörungen - Differentialdiagnose und Wirkungsmechanismen*. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-2007-1002216
53. Breault, M. S., Orguc, S., Kwon, O., Kang, G., Tseng, B., Schreier, D. R., & Brown, E. N. (2025). Anesthetics as Treatments for Depression: Clinical Insights and Underlying Mechanisms. Annual Review of Neuroscience. https://doi.org/10.1146/annurev-neuro-112723-062031
54. Brignole, M. (2006). Neurally mediated syncope. CRC Press eBooks. https://doi.org/10.1201/b13301-22
55. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1177/10598405050210060301
56. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1622/1059-8405(2005)021[0318:tuoais]2.0.co;2
57. Brody, D. L. (2019). Parkinsonism. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0020
58. Brola, W., Ziomek, M., & Czernicki, J. (2007). [Fatigue syndrome in chronic neurological disorders].. PubMed.
59. Browne, T. R., & Penry, J. K. (1973). Benzodiazepines in the Treatment of Epilepsy A Review. Epilepsia. https://doi.org/10.1111/j.1528-1157.1973.tb03965.x
60. Brust, J. C. (2002). Neurologic Complications of Substance Abuse. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/00126334-200210012-00002
61. Brust, J. C. (2002). Seizures and Illicit Drug Use. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_11
62. Budson, A. E., & O’Connor, M. K. (2021). Which medications can worsen thinking, memory, behavior, or function?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0012
63. Burk, A., Merchant, A., Rahman, H., Patel, A., Deshmukh, I., Merchant, R., Yam, A. A., Yu, A., Cai, C., Hassam, A., Le, D., & Lambroussis, C. G. (2025). Serotonin Syndrome Without Overdose: Polypharmacy-Induced Toxicity in a Medically Stable Young Adult. Cureus. https://doi.org/10.7759/cureus.86587
64. Burkhart, P. W. M. K. K. (2014). Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. Journal of Blood Disorders & Transfusion. https://doi.org/10.4172/2155-9864.1000195
65. Cano‐Vindel, A., Miguel-Tobal, J. J., González, H. M., & Díez, I. I. (1994). El afrontamiento de la ansiedad en las drogodependencias. Anales de Psicología.
66. Carrera, M. A. V., Correa, S. M. V., Prado, M. M. C., & Granados, K. P. M. (2019). Manejo de intoxicación por opioides. RECIMUNDO. https://doi.org/10.26820/recimundo/3.(4).diciembre.2019.494-510
67. Catalano, G., Catalano, M. C., & Rodríguez, R. (1997). Dystonia Associated With Crack Cocaine Use. Southern Medical Journal. https://doi.org/10.1097/00007611-199710000-00017
68. Catts, V. S., & Catts, S. V. (2010). Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia?. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511789977.011
69. Cavalheiro, É. A., Leite, J. P., Bortolotto, Z. A., Turski, W. A., Ikonomidou, C., & Turski, L. (1991). Long‐Term Effects of Pilocarpine in Rats: Structural Damage of the Brain Triggers Kindling and Spontaneous I Recurrent Seizures. Epilepsia. https://doi.org/10.1111/j.1528-1157.1991.tb05533.x
70. Cerbo, R., Barbanti, P., Fabbrini, G., Pascali, M. P., & Catarci, T. (1998). Amitriptyline Is Effective in Chronic But Not in Episodic Tension‐Type Headache: Pathogenetic Implications. Headache The Journal of Head and Face Pain. https://doi.org/10.1046/j.1526-4610.1998.3806453.x
71. Chandler, C. (2010). Glossary. https://doi.org/10.1002/9781444328172.gloss
72. Chaslerie, A., Bannwarth, B., Schaeverbeke, T., Vinçon, G., Dehais, J., & Bégaud, B. (1992). [Mode of action of non-narcotic analgesics].. PubMed.
73. Chazan, S., Ekstein, M., Marouani, N., & Weinbroum, A. A. (2018). Ketamine for acute and subacute pain in opioid-tolerant patients. Journal of Opioid Management. https://doi.org/10.5055/jom.2008.0023
74. Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation. Cambridge Quarterly of Healthcare Ethics. https://doi.org/10.1017/s0963180123000270
75. Chitsaz, A. (2017). Stroke And Substance Abuse. Advances in Bioscience and Clinical Medicine. https://doi.org/10.7575/aiac.abcmed.ca1.34
76. Cho, I., Chang, H. J., Lee, K. E., Won, H. S., Choi, M. Y., Nam, E. M., Mun, Y., Lee, S. N., & Seong, C. (2009). A Case of Wernicke's Encephalopathy Following Fluorouracil-based Chemotherapy. Journal of Korean Medical Science. https://doi.org/10.3346/jkms.2009.24.4.747
77. Chou, R., Norris, S. L., Carson, S., & Chan, B. (2007). Drug Class Review: Drugs for Neuropathic Pain: Final Report [Internet].
78. Chung, S., Oh, K., Cho, K., & Hwang, I.-K. (2003). Antidepressant-Induced Somnambulism：A Case of Mirtazapine. Sleep Medicine and Psychophysiology.
79. Cianchetti, C., Pruna, D., & Ledda, M. (2013). Epileptic seizures and headache/migraine: A review of types of association and terminology. Seizure. https://doi.org/10.1016/j.seizure.2013.05.017
80. Ciraulo, D. A., & Shader, R. I. (1990). Fluoxetine Drug-Drug Interactions. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199002000-00009
81. Citver, A. S., Shields, A. M., Ciaccia, L. M., Schulingkamp, R., & Raffa, R. B. (2002). Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1046/j.1365-2710.2002.00410.x
82. Clayton, A., Dennerstein, L., Pyke, R. E., & Sand, M. (2010). Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women. Women s Health. https://doi.org/10.2217/whe.10.54
83. COGEN, F. C. (1978). Phencyclidine-Associated Acute Rhabdomyolysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-88-2-210
84. Cohn, L. M., & Caliendo, G. C. (1997). Guanfacine use in children with attention deficit hyperactivity disorder.. PubMed.
85. Cole, J., & Katz, M. M. (1964). THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW.. PubMed.
86. Cole, J., & Katz, M. M. (1964). The Psychotomimetic Drugs. JAMA. https://doi.org/10.1001/jama.1964.03060230086021
87. Collu, A., Montaldo, S., Nonnoi, V., Campus, A., Pillai, G., Pinna, M., Primavera, D., & Carpiniello, B. (2007). Insomnia and excessive daytime sleepiness in psychotic patients taking traditional or atypical antipsychotic medications. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.527
88. Consroe, P., & Snider, S. R. (2019). Therapeutic Potential of Cannabinoids in Neurological Disorders * , †. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-2
89. Cook, B. A., & Spence, A. (1997). Post-operative central anticholinergic syndrome. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199701000-00001
90. Corales, R. L. (1980). Phencyclidine Abuse Mimicking Head Injury. JAMA. https://doi.org/10.1001/jama.1980.03300480043024
91. Cornejo, W., Ortiz, B. R., & Blazicevich, L. (2012). Epidemiology of Tics. InTech eBooks. https://doi.org/10.5772/32426
92. Coutts, S. R., Smith, I., & Stirzaker, A. G. (2025). Clarithromycin-Induced Psychosis: When Is Delirium Not Delirium?. Cureus. https://doi.org/10.7759/cureus.93096
93. Dahiya, M., Pandya, A. D., Malhotra, D., & Patel, P. (2019). Antiepileptic drug-induced acute psychotic disorder in a nonepileptic patient: A definite prophecy. Apollo Medicine. https://doi.org/10.4103/am.am_47_19
94. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
95. Dauner, A., & Blair, D. (1990). AKATHISIA: When Treatment Creates a Problem. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/0279-3695-19901001-05
96. David, G., Monge, M. P., Arántzazu, D., Fernanda, A., Fernanda, T. M., Gemma, M., & Sandra, D. (2016). Schizophrenia and sexual desinhibition. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2162
97. Day, R. O., Johnson, A. G., & Seldon, W. A. (1990). A functional psychosis precipitated by quinidine. The Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.1990.tb125463.x
98. Defrin, R., Brill, S., Goor-Arieh, I., Wood, I., & Devor, M. (2019). “Shooting pain” in lumbar radiculopathy and trigeminal neuralgia, and ideas concerning its neural substrates. Pain. https://doi.org/10.1097/j.pain.0000000000001729
99. Dell’Osso, L., Lorenzi, P., Nardi, B., Carpita, B., Benedetti, F., & Cremone, I. M. (2023). Occurrence of Terrifying Nightmares after Few Days of Mirtazapine Use in Elderly Patients. Case Reports in Psychiatry. https://doi.org/10.1155/2023/8843206
100. Deluca, C. F., & Cashore, W. J. (2002). Congenital Familial Hypertonia. Clinical Pediatrics. https://doi.org/10.1177/000992280204100713
101. DeLuca, G. C., & Bartleson, J. D. (2010). When and How to Investigate the Patient with Headache. Seminars in Neurology. https://doi.org/10.1055/s-0030-1249221
102. Deng, S., Sheng, H.-Z., Zhou, Y., & Zhang, J. (2019). Whether we could forget pain or not after the scar healed? A discussion about changing the acute pain into chronic pain. Pain Clin J. https://doi.org/10.3760/cma.j.issn.1672-9633.2019.05.003
103. Diarra, É. A.-A., Chubaka-Magala, G., Agbo-Panzo, S., Folatet, P., Essoin, A., Kadjo, C., Offoumou, F., Amon-Tanoh, M., Tanoh, A., Yapo-Ehounoud, C., Doumbia-Ouattara, M., & Assi, B. (2025). Holmes Tremors in a 60-year-old Woman Following Primary Brainstem hemorrhage (PBH) Responsive to Standard Dose of Trihexyphenidyl: A case report and literature review. Journal of African clinical cases and reviews.. https://doi.org/10.70065/2592.jaccrafri.003l013005
104. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
105. Dietz, A. J. (1981). Amphetamine-like Reactions to Phenylpropanolamine. JAMA. https://doi.org/10.1001/jama.1981.03310310043020
106. Dietz, A. J. (1981). Amphetamine-like reactions to phenylpropanolamine. JAMA. https://doi.org/10.1001/jama.245.6.601
107. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
108. Dore, G., & Sweeting, M. (2006). Drug-Induced Psychosis Associated with Crystalline Methamphetamine. Australasian Psychiatry. https://doi.org/10.1080/j.1440-1665.2006.02252.x
109. Dubovický, M. (2010). Neurobehavioral manifestations of developmental impairment of the brain. Interdisciplinary Toxicology. https://doi.org/10.2478/v10102-010-0012-4
110. Duma, S., & Fung, V. S. (2019). Drug-induced movement disorders. Australian Prescriber. https://doi.org/10.18773/austprescr.2019.014
111. Eadie, M. J. (2006). Remediable shortcomings in applying clinical pharmacology to neurological practice. Future Neurology. https://doi.org/10.2217/14796708.1.6.747
112. Ecker, A. (1990). Pimozide Therapy for Trigeminal Neuralgia. Archives of Neurology. https://doi.org/10.1001/archneur.1990.00530040022011
113. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
114. Egger, C., Muehlbacher, M., Nickel, M., Geretsegger, C., & Stuppaeck, C. (2006). A review on hyponatremia associated with SSRIs, reboxetine and venlafaxine. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651500500410216
115. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
116. Fahn, S., Greene, P., Ford, B., & Bressman, S. (2003). Movement Disorders. https://doi.org/10.1007/978-1-4757-4552-8_9
117. Faingold, C. L., & Riaz, A. (2019). Neuronal Networks in Convulsant Drug-Induced Seizures. CRC Press eBooks. https://doi.org/10.1201/9780429262623-10
118. Fauman, B. J., Aldinger, G., Fauman, M. A., & Rosén, P. (1976). Psychiatric Sequelae of Phencyclidine Abuse. Clinical toxicology. https://doi.org/10.3109/15563657608988154
119. Fava, G. A., & Cosci, F. (2019). Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.19com12794
120. Fava, G. A., Benasi, G., & Cosci, F. (2017). The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders. Verhaltenstherapie. https://doi.org/10.1159/000460826
121. Fellner, S. K. (1969). The clinical syndrome of analgesic abuse. Archives of Internal Medicine. https://doi.org/10.1001/archinte.124.3.379
122. Fellner, S. K. (1969). The Clinical Syndrome of Analgesic Abuse. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1969.00300190119021
123. Fernandez-Robles, C., Beach, S. R., & Fricchione, G. L. (2015). Somatic Therapies in the Treatment of Catatonia. Future Neurology. https://doi.org/10.2217/fnl.15.32
124. Fernández, C. (2014). Differential modulation by Sigma-1 receptors of µ opioid-induced antinociception and side effects : role of periperial sigma-1 receptors.
125. Ferro, J. M., & Bentes, C. (2006). Post-stroke epilepsy. Aging Health. https://doi.org/10.2217/1745509x.2.4.599
126. Finsterer, J., & Strobl, W. M. (2010). Presentation, Etiology, Diagnosis, and Management of Camptocormia. European Neurology. https://doi.org/10.1159/000314897
127. Firooz, M., Hosseini, S. R., & Hosseini, S. J. (2023). Valsalva maneuver: An effective non-pharmacological technique for pain management in nursing procedures. Journal of Nursing Reports in Clinical Practice. https://doi.org/10.32598/jnrcp.23.1
128. Fisher, H. J., & Bannister, A. K. (1953). Suxethonium Bromide in E.C.T.. Journal of Mental Science. https://doi.org/10.1192/bjp.99.417.796
129. Foltyn, P., Groh, R., Pw, L., & Steinhaus, W. (1978). [Demonstrating the effectiveness of cerebroactive drugs in aged patients. Results of a randomized double-blind study of a vincamine containing special preparation].. PubMed.
130. Forster, F. M., Richards, J., Panitch, H., Huisman, R. E., & Paulsen, R. E. (1975). Reflex Epilepsy Evoked by Decision Making. Archives of Neurology. https://doi.org/10.1001/archneur.1975.00490430076015
131. Franjić, S. (2023). Post-Traumatic Stress Disorder Appears as a Traumatic Experience. https://doi.org/10.61440/jcpn.2023.v1.04
132. Frankenburg, F. R., & Zanarini, M. C. (1994). Uses of Clozapine in Nonschizophrenic Patients. Harvard Review of Psychiatry. https://doi.org/10.3109/10673229409017130
133. Freitas, D. F. D., Teixeira-Ribeiro, R., Bouça, J., Fernandes, N., Duarte, J., & Morgado, P. (2015). Metformin-induced Psychosis: a Case Report.. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31423-1
134. Gamo, J. V., Palomeque, G. M., Soria, M. J. Á., Barragán, J. M. F., Alonso, R. I., & Cabello, J. (2010). Mioclonías de origen propioespinal y radicular: respuesta al levetiracetam. Revista de Neurología. https://doi.org/10.33588/rn.5102.2009669
135. Gangula, P. K. R. P., Samarla, P. K., Krishnasamy, M. J., Saravanan, S. V., Raman, S. P., Vellaichamy, K., Raju, V. S., & Krishnan, M. (2023). Myokymia in a Patient with Chronic Inflammatory Demyelinating Polyradiculoneuropathy.. PubMed. https://doi.org/10.59556/japi.71.0408
136. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
137. Garg, T., & Rawat, V. S. (2023). Trihexyphenidyl Use Disorder and Withdrawal Syndrome. Journal of Psychiatry Spectrum. https://doi.org/10.4103/jopsys.jopsys_12_23
138. Garro, A., Bond, G. R., & Gilbert, D. L. (2007). Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clinical Toxicology. https://doi.org/10.1080/15563650600981178
139. Gelenberg, A. J. (1977). Catatonic Reactions to High-Potency Neuroleptic Drugs. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1977.01770200085010
140. Georgotas, A., McCue, R. E., Friedman, E., & Cooper, T. B. (1987). Response of Depressive Symptoms to Nortriptyline, Phenelzine and Placebo. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.151.1.102
141. Gerancher, J. C. (1997). Cauda Equina Syndrome following a Single Spinal Administration of 5% Hyperbaric Lidocaine through a 25-gauge Whitacre Needle. Anesthesiology. https://doi.org/10.1097/00000542-199709000-00031
142. Ghaisani, N. (2018). Potensi Ketamin Dosis Rendah untuk Penderita Depresi Berat. JIMKI Jurnal Ilmiah Mahasiswa Kedokteran Indonesia.
143. Ghosh, P., & Desousa, A. (2024). Psychedelics: The New Kid on the Block. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_195_23
144. Glass, J. D. (1990). Wilson's Disease. Archives of Neurology. https://doi.org/10.1001/archneur.1990.00530050119022
145. Gloth, F. M. (1991). Can Vitamin D Deficiency Produce an Unusual Pain Syndrome?. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1991.00400080144029
146. GOEKE, J. E., Hagan, D., Goelzer, S. L., & Coursin, D. B. (1991). Lethal catatonia complicated by the development of neuroleptic malignant syndrome in a middle-aged female. Critical Care Medicine. https://doi.org/10.1097/00003246-199111000-00023
147. Goldberg, S. C. (1967). Prediction of Improvement in Schizophrenia Under Four Phenothiazines. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1967.01730190109015
148. Goldfeder, S., Scott, R., & Briggs, J. P. (2023). Forensic Assessments of Alcohol, Cannabis and Methamphetamine Intoxication in Cases of Violent Offending.. PubMed.
149. Goldstein, L. H., Mordish, Y., Abu-kishak, I., Toledano, M., & Berkovitch, M. (2006). Acute Paralysis Following Recreational MDMA (Ecstasy) Use. Clinical Toxicology. https://doi.org/10.1080/15563650600584600
150. Golovenko, N. Y. (2018). A pharmacological profile of propoxazepam — a new antiepileptic substance. Reports of the National Academy of Sciences of Ukraine. https://doi.org/10.15407/dopovidi2018.12.098
151. Gordon, N. (1979). Fetal Drug Syndromes. Neuropediatrics. https://doi.org/10.1055/s-0028-1085358
152. Graddy, R., & Rastegar, D. A. (2025). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0008
153. Grimmer, K., Larsen, T. M., & Kumar, S. (2004). Effectiveness of manipulation and mobilisation for headaches: an evidence-based systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2004-665
154. Group, M. T., Mackway‐Jones, K., Marsden, J., & Windle, J. (2006). Discriminator Dictionary. https://doi.org/10.1002/9780470757321.oth3
155. Grover, D., Vk, Y., & Ms, K. (1986). Improvement of phencyclidine-associated psychosis with ECT.. PubMed.
156. Guedj, M.-J. (2003). [Emergency situations in psychiatry].. PubMed.
157. Gupta, A., Jain, S., Sharma, Y., Vijay, P., & Saldhana, D. (2023). A case of incomplete Klippel-Trenaunay syndrome with schizophrenia and global cerebral atrophy. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_240_21
158. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
159. Hall, S., & Ibrahim, S. (2023). 0998 Duloxetine as a Possible Effective Treatment of Klein-Levin Syndrome Case Report. SLEEP. https://doi.org/10.1093/sleep/zsad077.0998
160. Hamani, C., & Lozano, A. M. (2003). Physiology and Pathophysiology of Parkinson's Disease. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2003.tb07459.x
161. Hamdan, M. (2013). Movement Disorder After Stroke.
162. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
163. Handler, C., Bessè, C., & Wilson, A. O. (1982). Extrapyramidal and cerebellar syndrome with encephalopathy associated with cimetidine. Postgraduate Medical Journal. https://doi.org/10.1136/pgmj.58.682.527
164. Hao, Y., Controzzi, M., Cipriani, C., Popović, D. B., Yang, X., Chen, W., Zheng, X., & Carrozza, M. C. (2013). Controlling hand-assistive devices: utilizing electrooculography as a substitute for vision. IEEE Robotics & Automation Magazine. https://doi.org/10.1109/mra.2012.2229949
165. Harangozó, J., Magyar, I., & Faludy, G. (1991). Use of benzodiazepines in psychiatry.. PubMed.
166. Hart, G. R., & Anderson, R. J. (1981). Withdrawal syndromes and the cessation of antihypertensive therapy.. PubMed.
167. Hassel, B., Rogne, A. G., & Hope, S. (2019). Intellectual Disability Associated With Pyridoxine-Responsive Epilepsies: The Need to Protect Cognitive Development. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2019.00116
168. Hayati, F., Nasouti, M. A., Shayanpour, S., & Halili, S. A. (2017). Administration of baclofen in end-stage renal disease. Journal of Renal Endocrinology.
169. Haywood, P., Divekar, N., & Karalliedde, L. (1999). Concurrent medication and the neuromuscular junction. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199902000-00002
170. Hm, W., Windorfer, A., & Stünkel, S. (1977). [Laboratory controls in long-term treatment with anticonvulsive drugs (author's transl)].. PubMed.
171. Hoehn‐Saric, R., Lipsey, J. R., & McLeod, D. R. (1990). Apathy and Indifference in Patients on Fluvoxamine. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199010000-00007
172. Holgate, S. T. (2002). Considerations on third generation antihistamines. Clinical & Experimental Allergy. https://doi.org/10.1046/j.1365-2222.2002.01339.x
173. Holla, S., Amberkar, M. B., Bhandarypanambur, R., Kumari, M., & Janardhanan, M. (2015). Cycloserine Induced Late Onset Psychosis and Ethambutol Induced Peripheral Neuropathy Associated with MDR-TB Treatment in an Indian Patient- A Rare Case Report. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. https://doi.org/10.7860/jcdr/2015/12417.5588
174. Hollister, L. E. (1978). Drug Spotlight Program: Treatment of Depression with Drugs. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-89-1-78
175. Ht, M. (1991). Diagnosis and management of phencyclidine intoxication.. PubMed.
176. Ingram, D. G., & Hagemann, T. M. (2003). Promethazine Treatment of Steroid-Induced Psychosis in a Child. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1a271
177. Ingram, T. T. S. (1956). A Characteristic Form of Overactive Behaviour in Brain Damaged Children. Journal of Mental Science. https://doi.org/10.1192/bjp.102.428.550
178. Iqbal, S., & Srivatsav, C. B. P. (1984). Chloramphenicol ototoxicity. A case report.. PubMed.
179. Iqbal, S., & Srivatsav, C. B. P. (1984). Cholarmphenicol ototoxicity. The Journal of Laryngology & Otology. https://doi.org/10.1017/s0022215100147000
180. Ismail, E., Shopov, G., & Radeva, M. (2016). Muscle relaxants in the anesthetic practice - clinical risks. Scripta Scientifica Pharmaceutica. https://doi.org/10.14748/ssp.v3i0.2437
181. ITTL, T. M., & Wadud, A. (1975). TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-197502000-00003
182. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Psychedelics. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380538.003.0606
183. Jacob, M. S., Carlen, P. L., Marshman, J. A., & Sellers, E. M. (1981). Phencyclidine Ingestion: Drug Abuse and Psychosis. International Journal of the Addictions. https://doi.org/10.3109/10826088109038866
184. Jacobs, D. H. (2007). Psychiatric Drugging: Forty Years of Pseudo-Science, Self-Interest, and Indifference to Harm.
185. Janowsky, D. S. (1973). Provocation of Schizophrenic Symptoms by Intravenous Administration of Methylphenidate. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1973.01750320023004
186. Jansen, K. (1990). Ketamine–Can Chronic Use Impair Memory. International Journal of the Addictions. https://doi.org/10.3109/10826089009056204
187. Jansen, P. A. (2003). [Clinically relevant drug interactions in the elderly].. PubMed.
188. Jc, L., & Jp, D. (1978). [Dyskinetic syndromes in psychiatric patients (author's transl)].. La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris.
189. Jia, S., Yu, Z., & Bai, L. (2023). Exerkines and osteoarthritis. Frontiers in Physiology. https://doi.org/10.3389/fphys.2023.1302769
190. Jl, M., Llau, M. E., Rascol, O., & Sénard, J. (1994). Drug‐induced parkinsonism: a review. Fundamental and Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.1994.tb00808.x
191. Jo, H.-S., Wang, S., & Kim, J. (2019). Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report. Clinical Psychopharmacology and Neuroscience. https://doi.org/10.9758/cpn.2019.17.1.130
192. Jong, M. H. D., Eussen, M., & Gool, A. R. V. (2010). [Antipsychotic agents and stimulants: a judicious combination?].. PubMed.
193. Jonge, M. E. A.-D., Portier, C., & Franssen, E. J. F. (2007). [Automutilation after consumption of hallucinogenic mushrooms].. PubMed.
194. Joubert, J. (1990). Cysticercal meningitis--a pernicious form of neurocysticercosis which responds poorly to praziquantel.. PubMed.
195. Jourdet, N. (2018). Les céphalées par abus médicamenteux : Prévention par le bon usage des médicaments indiqués dans les céphalées primaires. Usage problématique des opioïdes.
196. Kaliora, S. (2021). Electroconvulsive therapy in treatment resistant depression: What is new?. Psychiatriki. https://doi.org/10.22365/jpsych.2021.053
197. Kalita, J., & Misra, U. K. (2011). Management of provoked seizure. Annals of Indian Academy of Neurology. https://doi.org/10.4103/0972-2327.78041
198. Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011). The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal. https://doi.org/10.3402/ehtj.v4i0.7107
199. Kanchanatawan, B., & Kasantikul, D. (2007). Antipsychotic-induced tardive movement disorders: a series of twelve cases.. PubMed.
200. Kapoor, K. (2003). Novel Potential Antimigraine Compounds: Carotid and Systemic Haemodynamic Effects in a Porcine Model of Migraine.
201. Keam, S. J., & Walker, M. C. (2007). Therapies for narcolepsy with or without cataplexy: evidence-based review. Current Opinion in Neurology. https://doi.org/10.1097/wco.0b013e3282f22ad9
202. Keckich, W. A. (1978). Neuroleptics. JAMA. https://doi.org/10.1001/jama.1978.03290200063026
203. Keckich, W. A. (1978). Neuroleptics. Violence as a manifestation of akathisia. JAMA. https://doi.org/10.1001/jama.240.20.2185
204. KEELER, M. H., Reifler, C. B., & Liptzin, M. B. (1968). Spontaneous Recurrence of Marihuana Effect. American Journal of Psychiatry. https://doi.org/10.1176/ajp.125.3.384
205. Kerchner, G. A., & Rosenbloom, M. (2014). Frontotemporal Neurocognitive Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg65
206. Keyser, D. L. (1991). Neuroleptic Malignant Syndrome in Parkinson's Disease After Withdrawal or Alteration of Dopaminergic Therapy. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1991.00400040130031
207. Khadka, S., Singh, P., Khadka, M., Chakrabarti, K., Pandit, S., Dhonju, G., & Gautam, S. (2019). A Case Report On Fluoro-Quinolones (Ofloxacin) Induced Psychosis At Nepal Medical College Teaching Hospital. Journal of Psychiatrists Association of Nepal. https://doi.org/10.3126/jpan.v8i2.28029
208. Khan, A. R., Carolan, J., Rullo, M. J., Hamilton, K. L., Movsesova, T., Barseghian, B. A., Tsai, P., & Schreiber, J. F. (2023). Steroid-Responsive Encephalopathy associated with Autoimmune Thyroiditis (SREAT) presenting as malignant excited catatonia: A novel clinical presentation. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100198
209. Killick, L., Carlyle, W., & Ancill, R. (1991). ECT: An Effective Treatment in the Screaming Demented Patient. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1991.tb03610.x
210. Kimball, A. B., & Grossman, S. A. (2017). Syncope And Related Paroxysmal Spells.
211. Klepstad, P., & Rosland, J. H. (2011). No pain, much gain. Acta Anaesthesiologica Scandinavica. https://doi.org/10.1111/j.1399-6576.2010.02379.x
212. Knopp, M., Srikantha, M., & Rajabally, Y. A. (2013). Insulin Neuritis and Diabetic Cachectic Neuropathy: A Review. Current Diabetes Reviews. https://doi.org/10.2174/1573399811309030007
213. Kokaçya, M. H., Çöpoğlu, Ü. S., Şahpolat, M., & Arı, M. (2016). Use of Modafinil in Psychiatric Disorders. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry.
214. Kollins, S. H. (2003). Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.. PubMed.
215. Koshy, R., & Sudha, P. (2011). Nonconvulsive status epilepticus: An unusual cause of postoperative unresponsiveness following general anaesthesia. Indian Journal of Anaesthesia. https://doi.org/10.4103/0019-5049.79901
216. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
217. Krantz, D. S., Gabbay, F. H., Hedges, S. M., Klein, J., NEBEL, L. E., Helmers, K. F., Patterson, S., SAMETH, J. L., Gottdiener, J. S., & Rozanski, A. (1991). Behavioral Triggers of Silent and Symptomatic Myocardial Ischemia. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/j.1540-8167.1991.tb01376.x
218. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część II. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.33
219. Kumar, S., & Browne, M. O. (2003). What are the effects of drug treatments for panic disorder?. Evidence-Based Mental Health. https://doi.org/10.1136/ebmh.6.2.34
220. Kutlay, M., Cemil, B., Kaya, Ş. Ö., Topuz, K., & Demircan, M. N. (2010). A Rare Case of Occipital Neuralgia Secondary to Ball Bullet Gunshot Wound. Central European Neurosurgery. https://doi.org/10.1055/s-0030-1247563
221. Lai, M.-H. (2007). Choreoathetosis as Side Effect of Gabapentin Therapy in a Patient with Spontaneous Spinal Epidural Hematoma: A casereport. Deleted Journal. https://doi.org/10.6315/2007.35(3)08
222. Lam, L., Liu, V. W. C., & Chiu, H. F. (2002). Antidepressants for the Treatment of Neuropathic Pain. Hong Kong journal of psychiatry.
223. Lambert, M., Schimmelmann, B. G., Karow, A., & Naber, D. (2003). Subjective Well-being and Initial Dysphoric Reaction under Antipsychotic Drugs - Concepts, Measurement and Clinical Relevance. Pharmacopsychiatry. https://doi.org/10.1055/s-2003-45128
224. Lammers, M., & Ahmed, A. (2013). Melatonin for Sundown Syndrome and Delirium in Dementia: Is It Effective?. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12296
225. Lansink, J. G. H., Oosterhout, W. P. J. R. V., Borggreve, A. G. M. F., & Haan, J. (2014). [Footballer's migraine instead of concussion].. PubMed.
226. Lawson, K., Singh, A., Kantsedikas, I., Jenner, C. A., & Austen, D. K. (2021). Flupirtine as a Potential Treatment for Fibromyalgia. Journal of Exploratory Research in Pharmacology. https://doi.org/10.14218/jerp.2020.00043
227. Lee, H., Kim, J., Lee, H.-S., Jo, Y.-H., Ko, J.-A., In, S., & Lee, J.-B. (2023). MS Fragmentation of ALD-52 with GC-MS and LC-QTOF. Korean Journal of Forensic Science. https://doi.org/10.53051/ksfs.2023.24.1.2
228. Lee, K., Jenkins, K. D., & Sparkle, T. (2021). A Narrative Overview of Current Anesthetic Drugs in Electroconvulsive Therapy. Life. https://doi.org/10.3390/life11090981
229. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
230. Lerner, S. E., & Burns, R. S. (1978). Phencyclidine use among youth: history, epidemiology, and acute and chronic intoxication.. PubMed.
231. Lerner, S. E., Burns, R. S., Corrado, R. R., James, S., & Schnoll, S. H. (1975). Phencyclidine--states of acute intoxication and fatalities.. PubMed.
232. Lewis, J. W., Cannon, J. T., & Liebeskind, J. C. (1980). Opioid and Nonopioid Mechanisms of Stress Analgesia. Science. https://doi.org/10.1126/science.7367889
233. Liegl, U., & Martinius, J. (1991). [Inadequacy of the "hyperkinetic syndrome" diagnosis and practical consequences].. PubMed.
234. Linton, H. B. (1962). Subjective Reactions to Lysergic Acid Diethylamide (LSD-25). Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1962.01710230020003
235. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
236. Llorente, J. M., & Martínez, E. R. (2010). Otros trastornos no motores en la enfermedad de Parkinson. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009743
237. Lo, S. E., & Frucht, S. J. (2012). Myoclonus. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-120-2_5
238. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
239. Logan, B. K., Yeakel, J. K., Goldfogel, G. A., Frost, M., Sandstrom, G., & Wickham, D. J. (2012). Dextromethorphan Abuse Leading to Assault, Suicide, or Homicide. Journal of Forensic Sciences. https://doi.org/10.1111/j.1556-4029.2012.02133.x
240. Loprinzi, C. L., Maddocks‐Christianson, K., Wolf, S. L., Rao, R. D., Dyck, P. J. B., Mantyh, P. W., & Dyck, P. J. B. (2007). The Paclitaxel Acute Pain Syndrome: Sensitization of Nociceptors as the Putative Mechanism. The Cancer Journal. https://doi.org/10.1097/ppo.0b013e31815a999b
241. Lorusso, A. M., Bruno, S., & L'Abbate, N. (2006). [Occupational fitness of workers with fibromyalgia syndrome].. Giornale italiano di medicina del lavoro ed ergonomia.
242. Lowenstein, D. H., & Simon, R. P. (2019). Antiepileptic Drugs Useful in Status Epilepticus. CRC Press eBooks. https://doi.org/10.1201/9780429262623-29
243. Lutrand, J. C., & Ducamin, J. P. (1978). [Dyskinetic syndromes in psychiatric patients (author's transl)].. PubMed.
244. López, A. M., Martínez, L. R. D., & Moreno, J. (2012). Uso de marcadores bioquímicos para valoración de riesgo de crisis convulsivas en el síndrome de supresión etílica. Salud Mental.
245. Machek, S. B. (2019). Psychedelics: Overlooked Clinical Tools with Unexplored Ergogenic Potential.
246. Mailman, R. B., & Murthy, V. (2010). Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?. Current Pharmaceutical Design. https://doi.org/10.2174/138161210790361461
247. Maio, V. D., & Maio, T. D. (2005). Excited Delirium Syndrome: Cause of Death and Prevention.
248. Malin, H., & Saleh, F. M. (2007). Paraphilias: Clinical and Forensic Considerations.
249. Mander, A., McCausland, M., Workman, B., Flamer, H., & Christophidis, N. (1994). Fluoxetine Induced Dyskinesia. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1080/00048679409075647
250. Mander, A., McCausland, M., Workman, B., Flamer, H., & Christophidis, N. (1994). Fluoxetine induced dyskinesia. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.3109/00048679409075647
251. Manfredi, R. L., & Kales, A. (1987). Clinical Neuropharmacology of Sleep Disorders. Seminars in Neurology. https://doi.org/10.1055/s-2008-1041429
252. Manjunatha, N., Vidyendaran, R., Rao, M., Kulkarni, G. B., Muralidharan, K., John, J. P., Amar, B. R., & Jain, S. (2010). Subacute vocal cord paralysis, facial palsy and paraesthesias of lower limbs following surreptitious administration of disulfiram. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2009.190397
253. Mannerkorpi, K., & Salo, P. (2014). Assessment of muscle strength and muscle function in fibromyalgia. https://doi.org/10.2217/fmeb2013.13.83
254. Marcianò, G., Evangelista, M., Vocca, C., Rania, V., Palleria, C., Caroleo, M. C., Torta, R., & Gallelli, L. (2025). Pregabalin and Duloxetine in Patients with Non-Nociceptive Pain: A Narrative Review Exploring the Pharmacological Effects of This Combination. Pharmaceuticals. https://doi.org/10.3390/ph18101434
255. Marder (2006). A review of agitation in mental illness: treatment guidelines and current therapies.. PubMed.
256. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
257. Masmoudi, K., Masson, H., Gras, V., & Andréjak, M. (2011). Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundamental and Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.2011.01008.x
258. Matute, M. S., Matute, R., & Merino, P. (2016). Design and Synthesis of Dopaminergic Agonists. Current Medicinal Chemistry. https://doi.org/10.2174/0929867323666160504103621
259. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
260. Maxwell, R. A., & Eckhardt, S. B. (1990). Imipramine. Drug Discovery. https://doi.org/10.1007/978-1-4612-0469-5_10
261. Mayfield, D. G., Kirubakaran, V., & Rengachary, S. S. (1984). Dyskinesia and psychosis in a patient following baclofen withdrawal. American Journal of Psychiatry. https://doi.org/10.1176/ajp.141.5.692
262. Mačugová, A., Kuželová, M., Kostková, L., Drobná, V., Luha, J., Dukát, A., Murín, J., Stratený, K., & Wawruch, M. (2011). Anticholínergické účinky liečiv u starších pacientov. Klinická farmakologie a farmacie.
263. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
264. Medini, F., Menif, L., Jmii, G., Ghali, F., Zeghal, M., Robbana, L., Derouiche, S., & Melki, W. (2016). Doctor I have painful erections. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2020
265. Meltzer, H. Y. (2007). Atypical Antipsychotic Drugs: Mechanism of Action. https://doi.org/10.1002/9780470101001.hcn034
266. Mendizabal, J. E., & Zweifler, R. M. (1998). Treatment of Neuropathic Pain. Journal of Pharmacy Practice. https://doi.org/10.1177/089719009801100508
267. Meneses, A. (2013). 5-HT systems: emergent targets for memory formation and memory alterations. Reviews in the Neurosciences. https://doi.org/10.1515/revneuro-2013-0026
268. Miceli, F., Soldovieri, M. V., Joshi, N., Weckhuysen, S., Cooper, E. C., & Taglialatela, M. (2016). KCNQ2-Related Disorders.
269. Mikellides, G., & Kyriazis, M. (2025). Psychedelics and mental health: reimagining care through science, insight, and compassion. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1649929
270. Millichap, J. G. (1968). Drugs in Management of Hyperkinetic and Perceptually Handicapped Children. JAMA. https://doi.org/10.1001/jama.1968.03150070065010
271. Millichap, J. G. (1968). Drugs in management of hyperkinetic and perceptually handicapped children.. PubMed.
272. Milán, E. P., Gómez, M. A. R., Gutiérrez, F. V., & González, V. M. (2003). Nefritis intersticial inducida por oxcarbacepina en un paciente con síndrome de hipersensibilidad a fármacos. Revista de Neurología. https://doi.org/10.33588/rn.3710.2003242
273. Mizukami, K., Naito, Y., Yoshida, M., Nakanishi, T., & Koizumi, J. (1990). Mental Disorders Induced by Carbamazepine. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.1990.tb00441.x
274. Moh, D., & Sansone, R. A. (2015). Factitious Disorder Manifesting as Hematemesis and Hematochezia. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.14l01693
275. Mohanty, I., Arunvikram, K., Sardar, K. K., Palai, S., Sahoo, G., & Patra, R. C. (2014). Adverse drug reaction and toxicity caused by commonly used antimicrobials in canine practice. Veterinary World. https://doi.org/10.14202/vetworld.2014.299-305
276. Montoya-Cabrera, M. A. (1990). [Poisoning caused by neuroleptics and other related drugs].. PubMed.
277. Morgante, F., Rosa, A. E. D., Meduri, M., Musolino, R., Leggiadro, N., Coraci, M., Crisafulli, A., & Perri, R. D. (1987). Parkinson-like side effects during prolonged treatment with flunarizine.. PubMed.
278. Moscovich, M., Estupinan, D., Qureshi, M. Y., & Okun, M. S. (2013). Shell shock: Psychogenic gait and other movement disorders—A film review. Tremor and Other Hyperkinetic Movements. https://doi.org/10.5334/tohm.132
279. Mosiołek, A., & Galanty, D. (2017). Wszystko co powinniśmy wiedzieć o złośliwym zespole neuroleptycznym.
280. Mostafa, K., Kelbrick, M., Mustafa, A., Willis, G., & Paduret, G. (2024). Acute psychosis following baclofen overdose. Progress in Neurology and Psychiatry. https://doi.org/10.1002/pnp.837
281. Mountney, A., Shear, D. A., Potter, B., Marcsisin, S. R., Sousa, J., Meléndez, V., Tortella, F. C., & Lu, X. M. (2013). Ethosuximide and Phenytoin Dose-Dependently Attenuate Acute Nonconvulsive Seizures after Traumatic Brain Injury in Rats. Journal of Neurotrauma. https://doi.org/10.1089/neu.2013.3001
282. Mozayani, A. (2003). Phencyclidine - Effects on Human Performance and Behavior.. PubMed.
283. Mukherji, S., Shoaib, H., & Jiménez, X. (2023). Brief case report: A case of FOLFIRI—Induced psychosis. Psycho-Oncology. https://doi.org/10.1002/pon.6206
284. Mukim, M., Devi, S. L., Sharma, P., Joshef, M. R., Nagar, J. C., & Ahmad, N. (2019). ANESTHESIA AND ITS APPPLICATION. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2019.6.4.5
285. Mula, M., Matteo, P., Basaglia, C., Favaretto, E., & Schwitzer, J. (2013). 2804 – Asenapine after clozapine: is possible?. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77392-9
286. Murasaki, M., & Takahashi, A. (2005). Drug Induced Movement Disorders. Wiley eBooks. https://doi.org/10.1002/9780470753217
287. Murillo, L. G., Calero-Fernandez, R., Fernandez, S. J., Estape, M. R., Serrano, E., Sánchez‐Herrero, E., & Iglesias, C. (2010). P03-330 Case Report: Serotonin Syndrome vs Neuroleptic Malignant Syndrom. European Psychiatry. https://doi.org/10.1016/s0924-9338(10)70936-6
288. Murphy, P. M., & Murphy, C. A. (2011). Hyperventilation as a Simple Cure for Severe Exercise-Associated Muscle Cramping. Pain Medicine. https://doi.org/10.1111/j.1526-4637.2011.01112.x
289. Möller, H., Lee, S., Lee, S.-Y., Seo, H.-J., Wang, S.-M., Park, M. H., Patkar, A. A., Koh, J. L., Masand, P. S., & Pae, C.-U. (2011). Available therapies and current management of fibromyalgia: Focusing on pharmacological agents. Drugs of today. https://doi.org/10.1358/dot.2011.47.7.1603503
290. Müller, D., Angerer, V., Kithinji, J., Auwärter, V., Neurath, H., Liebetrau, G., Just, S., & Hermanns‐Clausen, M. (2016). Desoxypipradrol – eine neue (alte) Designerdroge. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-0042-107537
291. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
292. Nakano, M., Funayama, M., Takata, T., Wakisaka, R., Koyama, G., Koreki, A., Ishida, T., Uchida, H., & Mimura, M. (2024). Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy. BMC Psychiatry. https://doi.org/10.1186/s12888-024-05846-5
293. Nauth-Misir, T. N. (1948). Case of Gross Overdosage of Soluble Phenytoin. BMJ. https://doi.org/10.1136/bmj.2.4578.646
294. Negri, A. M. (1994). Treatment‐resistant depression: Case report. Depression and Anxiety. https://doi.org/10.1002/depr.3050020508
295. Nelson, J. D., & Chouinard, G. (1999). Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.. PubMed.
296. Neubauer, D. N. (2007). Medication effects on sleep. CRC Press eBooks. https://doi.org/10.3109/9780203089897-16
297. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
298. Nicholson, T. R., Carson, A., Edwards, M. J., Goldstein, L. H., Hallett, M., Mildon, B., Nielsen, G., Nicholson, C., Perez, D. L., Pick, S., Stone, J., Anderson, D. G., Asadi‐Pooya, A. A., Aybek, S., Baslet, G., Bloem, B., Brown, R. J., Chalder, T., Damianova, M., ... Tinazzi, M. (2019). Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. Journal of Neuropsychiatry. https://doi.org/10.1176/appi.neuropsych.19060128
299. Nicolson, G. L., Nasralla, M. Y., Haier, J., & Nicolson, N. L. (1999). GULF WAR ILLNESSES: ROLE OF CHEMICAL, RADIOLOGICAL AND BIOLOGICAL EXPOSURES.
300. Niesters, M., Martini, C., & Dahan, A. (2013). Ketamine for chronic pain: risks and benefits. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.12094
301. Nijdam, S. J. (1990). [Anxiety and depression caused by side effects of drugs].. PubMed.
302. Noble, F., & Roques, B. P. (2003). Inhibitors of Enkephalin Catabolism. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_5
303. Noskoski, E., Leitner, C. M. K., Simes, M., Andrade, K. R. D., & Züge, S. S. (2021). FIBROMYALGIA: THE PATIENT'S PERCEPTION. SBR 2021 Congresso Brasileiro de Reumatologia. https://doi.org/10.47660/cbr.2021.2191
304. Nr, S., Gierz, M., Berkowitz, A., Nemiroff, R., & Lohr, J. B. (1990). Electroconvulsive therapy in a patient with severe tic and major depressive episode.. PubMed.
305. Nádvorník, P., Kolařík, J., & Drlicková (1990). Functional complications of therapeutic stimulation.. PubMed.
306. Obermann, M., & Holle, D. (2010). Hypnic headache. Expert Review of Neurotherapeutics. https://doi.org/10.1586/ern.10.112
307. Omote, K. (1997). Are intrinsic inhibitory systems activated or inhibited in pathological pain states?. Behavioral and Brain Sciences. https://doi.org/10.1017/s0140525x97461496
308. Ossipov, M. H., & Porreca, F. (2006). Mechanisms of pain facilitation systems: Implications for medication-overuse headache 185-193. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198569817.003.0025
309. Paganelli, F., Malaterre, H., Lauribe, P., Ramond, B., & Levy, S. W. (1992). [Parkinson syndrome, a possible adverse effect of calcium inhibitors].. PubMed.
310. Pakhale, K., & Bhate, A. (2014). USUAL ERRATIC PHENOMENON AND DRAMATIC OUTCOME A CASE REPORT OF PHENYTOIN TOXICITY. Journal of Evolution of Medical and Dental Sciences. https://doi.org/10.14260/jemds/2014/3905
311. Pandya, D., Shinkar, D. M., & Saudagar, R. B. (2016). Kleptomania: An overview. Asian Journal of Pharmacy and Technology. https://doi.org/10.5958/2231-5713.2016.00017.9
312. Paparrigopoulos, T., Tzavellas, E., Karaiskos, D., Kouzoupis, A. V., & Liappas, I. (2010). Complete recovery from undertreated Wernicke-Korsakoff syndrome following aggressive thiamine treatment..
313. Pareja, J. A., Palomo, T., Gorriti, M. Á., Pareja, J., & Espejo, J. M. C. (1990). “Hemicrania Episodica”‐A New Type of Headache or a Pre‐Chronic Stage of Hemicrania Continua?. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.1990.hed3006344.x
314. Parsa, A., Mohammadkhan, A., & Babaeian, M. (2017). Zolpidem-Induced Narcolepsy, Faint, Seizure or Coma? A Case Report. Case Reports in Clinical Medicine. https://doi.org/10.4236/crcm.2017.62004
315. Pechnick, R. N., Cunningham, K. A., & Danovitch, I. (2014). Hallucinogen-Related Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg51
316. Pendergraft, W. F., Herlitz, L., Thornley‐Brown, D., Rosner, M. H., & Niles, J. L. (2014). Nephrotoxic Effects of Common and Emerging Drugs of Abuse. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.00360114
317. Perrin, R., Edwards, J., & Hartley, P. (1998). An evaluation of the effectiveness of osteopathic treatment on symptoms associated with Myalgic Encephalomyelitis. A preliminary report. Journal of Medical Engineering & Technology. https://doi.org/10.3109/03091909809009993
318. Pfeiffer, C. R., & Wagner, M. (1994). Clozapine therapy for Parkinson’s disease and other movement disorders. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/51.24.3047
319. Pickard, H. (2011). What Is Personality Disorder?. Philosophy, psychiatry & psychology. https://doi.org/10.1353/ppp.2011.0040
320. Plavec, D., & Vuljanko, I. M. (2010). ANAFILAKSIJA POTAKNUTA NAPOROM.
321. Pombo, R., Johnson, E., Gamboa, A., & Omalu, B. (2017). Autopsy-proven Mirtazapine Withdrawal-induced Mania/Hypomania Associated with Sudden Death. Journal of Pharmacology and Pharmacotherapeutics. https://doi.org/10.4103/jpp.jpp_162_16
322. Price, A., Sumner, P., & Powell, G. (2025). The subtypes of visual hypersensitivity are transdiagnostic across neurodivergence, neurology and mental health. Vision Research. https://doi.org/10.1016/j.visres.2025.108640
323. Pérez‐Riera, A. R., Barbosa‐Barros, R., Raimundo, R. D., & Abreu, L. C. D. (2017). Main artifacts in electrocardiography. Annals of Noninvasive Electrocardiology. https://doi.org/10.1111/anec.12494
324. Păunica, S., Giurgiu, M., Vasilache, A., Păunică, I., Motofei, I. G., Vasilache, A., Dumitriu, H., & Dumitriu, A. S. (2016). Finasteride adverse effects and post-finasteride syndrome; implications for dentists. Journal of Mind and Medical Sciences. https://doi.org/10.22543/2392-7674.1039
325. Quadri, M. (2013). Finding Genes for Parkinsonism.
326. Rada, F. M., & Lucas-Taracena, M. T. D. (2006). [Swallowing phobia: symptoms, diagnosis and treatment].. PubMed.
327. Rahimibarghani, S., & Fateh, H. R. (2023). <scp>Long‐lasting</scp> mood deterioration following transcranial direct current stimulation treatment for fibromyalgia: A case report. Clinical Case Reports. https://doi.org/10.1002/ccr3.7712
328. Rainey, J. M., & Crowder, M. (1975). Prolonged psychosis attributed to phencyclidine: report of three cases. American Journal of Psychiatry. https://doi.org/10.1176/ajp.132.10.1076
329. Ranganathan, A., & Beitman, B. D. (1998). Panic disorder: a different perspective.. PubMed.
330. Rashed, K. (2021). Phytochemical and biological activities of khat (Catha edulis Forsk): A review. South Asian Journal of Agricultural Sciences.
331. Rasmussen, J., Malavé, A., Soto-Gomez, N., Romero, R., & Eckmann, M. (2013). Ketamine and Dexmedetomidine Coma in Complex Regional Pain Syndrome (P02.011). Neurology. https://doi.org/10.1212/wnl.80.7_supplement.p02.011
332. Rasmussen, K. G., & Ritter, M. J. (2014). Some Considerations of the Tolerability of Ketamine for ECT Anesthesia. Journal of Ect. https://doi.org/10.1097/yct.0000000000000100
333. Rasmussen, S., & Kristensen, M. B. (1977). Choreoathetosis during Phenytoin Treatment. Acta Medica Scandinavica. https://doi.org/10.1111/j.0954-6820.1977.tb15691.x
334. Rastegar, D. A., & Fingerhood, M. (2015). Cocaine, Methamphetamine, and Other Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0008
335. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
336. Rastegar, D. A., & Fingerhood, M. (2015). Marijuana and Other Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0010
337. Ray, A., Jc, S., & Gupta, M. (2013). Rifampicin induced adrenal crisis in an uncommon setting. Lung India. https://doi.org/10.4103/0970-2113.120626
338. Ray, C. (1978). Electrical stimulation: new methods for therapy and rehabilitation.. PubMed.
339. Reddy, S., & Kornblum, R. (1987). Rhabdomyolysis Following Violent Behavior and Coma. Journal of Forensic Sciences. https://doi.org/10.1520/jfs11160j
340. Reeves, R. R., Ladner, M. E., Perry, C. L., Burke, R. S., & Laizer, J. T. (2015). Abuse of Medications That Theoretically Are Without Abuse Potential. Southern Medical Journal. https://doi.org/10.14423/smj.0000000000000256
341. Reeves, R. R., Mack, J. E., & Beddingfield, J. J. (2003). Shock‐Like Sensations During Venlafaxine Withdrawal. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.23.5.678.32198
342. Richter, W., & Otto, C. (1997). [Hypoglycemia. Symptoms, differential diagnosis, therapy].. PubMed.
343. Riddle, M. A., King, R. A., Hardin, M. T., Scahill, L. D., Ort, S. I., Chappell, P., Rasmusson, A. M., & Leckman, J. F. (1990). Behavioral Side Effects of Fluoxetine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.1990.1.193
344. Robinson, C. P., & Hocker, S. E. (2019). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0098
345. Rodríguez, E. O., Martı́nez-Raga, J., Gómez, M. C., Gálvez, B. P., Ferragut, A. S., & Martínez, G. C. (2003). Complicaciones físicas del consumo de drogas recreativas. Adicciones. https://doi.org/10.20882/adicciones.462
346. Rohmayanti, I. D., & Kurniawan, S. N. (2023). POST HERPETIC NEURALGIA. JPHV (Journal of Pain Vertigo and Headache). https://doi.org/10.21776/ub.jphv.2023.004.01.1
347. Rosa, G. D., Spanò, M., Pustorino, G., Ferrari, M. D., Stam, A. H., Sgrò, D. L., Mannarino, E., Bonsignore, M. R., & Tortorella, G. (2006). Alternating hemiplegia of childhood successfully treated with topiramate: 18 months of follow-up. Neurology. https://doi.org/10.1212/01.wnl.0000191401.37260.f5
348. Rosli, A. (2017). Antidepressant Activity of Spirulina Platensis in Models of Depression. Psychology and Mental Health Care. https://doi.org/10.31579/2637-8892/003
349. Ružić, K., Grahovac, T., Graovac, M., Dadić-Hero, E., Šepić-Grahovac, D., & Sabljić, V. (2011). Hyperprolactinaemia with amisulpride.. PubMed.
350. Ryu, H. U., Kim, H. J., Shin, B., & Kang, H. G. (2024). Clinical approaches for poststroke seizure: a review. Frontiers in Neurology. https://doi.org/10.3389/fneur.2024.1337960
351. Saad, R. J., & Chey, W. D. (2006). Review article: current and emerging therapies for functional dyspepsia. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.03005.x
352. Saeed, M. A. A. (2017). Management of tinnitus patient. International Journal of Growth and Development. https://doi.org/10.25081/ijgd.2017.v1i1.44
353. Sahoo, M. K., & Biswas, H. (2021). Disulfiram-induced seizure in a patient with alcohol dependence syndrome. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_149_20
354. Salim, M. S., & Anjum, Q. (2003). Role of nerve blocks in chronic pain managementi. Rawal Medical Journal.
355. Sanger, T. D., Delgado, M. R., Gaebler‐Spira, D., Hallett, M., & Mink, J. W. (2003). Classification and Definition of Disorders Causing Hypertonia in Childhood. PEDIATRICS. https://doi.org/10.1542/peds.111.1.e89
356. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
357. Scheife, R., Hills, J. R., & Munsat, T. L. (1981). Myasthenia Gravis: Signs, Symptoms, Diagnosis, Immunology, and Current Therapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/j.1875-9114.1981.tb03552.x
358. Scott, M. (1968). Cranial Nerve Syndromes Relation to Exogenous And Endogenous Substances. JAMA. https://doi.org/10.1001/jama.1968.03140100075027
359. Segal, M. S. (2019). Cannabinoids and Analgesia. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-6
360. Seibert, L. M., & Crowell‐Davis, S. L. (2019). Antipsychotics. https://doi.org/10.1002/9781119226253.ch14
361. Sengstock, B., & Curtis, J. (2023). Excited delirium syndrome. Journal of Paramedic Practice. https://doi.org/10.12968/jpar.2023.15.8.cpd1
362. Seritan, A. L., Ortigas, M., Seritan, S., Bourgeois, J. A., & Hagerman, R. J. (2013). Psychiatric Disorders Associated with FXTAS. Current Psychiatry Reviews. https://doi.org/10.2174/157340013805289699
363. Seritan, A. L., Ortigas, M., Seritan, S., Bourgeois, J. A., & Hagerman, R. J. (2013). Psychiatric Disorders Associated with FXTAS. Current Psychiatry Reviews. https://doi.org/10.2174/1573400511309010009
364. Serrano, L., & Néstor, A. (2019). Proceso de Atención de Enfermería en neonato con diagnóstico de Síndrome de Abstinencia Neonatal, perteneciente al área CIN en el Hospital General Guasmo Sur..
365. Shah, S. M., Albin, R. L., & Baser, S. (2003). Movement Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511547256.014
366. Sharpe, M. (2010). Chronic fatigue syndrome (postviral fatigue syndrome, neurasthenia, and myalgic encephalomyelitis). Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260504
367. Shebani, Z., Walter, B., Masel, T., Patel, C., & Li, X. (2023). Cefepime-Induced Neurotoxicity or Nonconvulsive Status Epilepticus (NCSE): A Controversy Revisited. Cureus. https://doi.org/10.7759/cureus.38050
368. Shirata, T., Yano, S., Noto, K., Kanno, M., & Suzuki, A. (2023). Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective <scp>COX</scp>‐2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12325
369. SHOWALTER, C., & Thornton, W. E. (1977). Clinical pharmacology of phencyclidine toxicity. American Journal of Psychiatry. https://doi.org/10.1176/ajp.134.11.1234
370. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
371. Slater, R. J., & Yearwood, A. C. (1980). Facts, Faith, and Hope. AJN American Journal of Nursing. https://doi.org/10.2307/3470065
372. Snavely, S. R. (1984). The Neurotoxicity of Antibacterial Agents. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-101-1-92
373. Snyder, S. H., Faillace, L. A., & Weingartner, H. (1969). A New Psychotropic Agent. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1969.01740190097014
374. So, E. L., & Penry, J. K. (1981). Adverse Effects of Phenytoin on Peripheral Nerves and Neuromuscular Junction: A Review. Epilepsia. https://doi.org/10.1111/j.1528-1157.1981.tb06157.x
375. Solomon, D. A., & Barker, D. B. (1990). The Potential for Mental Status Changes Associated with Systemic Absorption of Anticholinergic Ophthalmic Medications: Concerns in the Elderly. DICP. https://doi.org/10.1177/106002809002400911
376. Soriano, A., Gutgsell, T. L., & Davis, M. P. (2013). Diencephalic Storms From Leptomeningeal Metastases and Leukoencephalopathy. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/1049909112472047
377. Spiegel, E. P., & Vanderploeg, R. D. (2010). Postconcussion Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0696
378. Sprenger, T., Valet, M., Hammes, M., Erhard, P., Berthele, A., Conrad, B., & Tölle, T. R. (2004). Hypothalamic Activation in Trigeminal Autonomic Cephalgia: Functional Imaging of an Atypical Case. Cephalalgia. https://doi.org/10.1111/j.1468-2982.2004.00753.x
379. Stannard, C., Coupe, M., & Pickering, T. (2013). Clinical use: neuropathic pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199678075.003.0012
380. Stevens, R. L., Pogrel, M. A., Bosack, R. C., & Orr, T. (2015). Complications with the use of Local Anesthetics. https://doi.org/10.1002/9781119053231.ch31
381. Stewart, M., & Turner, M. (1991). Reversal of unconsciousness by use of naloxone in a profoundly mentally handicapped epileptic. Journal of Intellectual Disability Research. https://doi.org/10.1111/j.1365-2788.1991.tb01035.x
382. Stoychev, K., Ivanov, K., Kojuharov, C., Khrusafov, D., Alexandrová, M., & Barkashka, D. (2016). ANTYPSYCHOTICS IN SCHIZOPHRENIA TREATMENT – LITERATURE REVIEW. Human Sport Medicine. https://doi.org/10.14529/hsm160304
383. Strassman, R. J. (1984). ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-198410000-00001
384. Sugimoto, A., Futamura, A., & Kawamura, M. (2013). [Epilepsy and cognitive dysfunction].. PubMed.
385. Svobodová, J., & Václavík, P. M. (2007). Detoxifikace u závislosti na metamfetaminu. Psychiatrie pro praxi.
386. Swaiman, K. F., & Frank, Y. (1978). Seizure Headaches in Children. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.1978.tb15276.x
387. Swartz, C. M. (1978). Lupus-like Reaction to Phenelzine. JAMA. https://doi.org/10.1001/jama.1978.03280520065024
388. Swartz, C. M. (2002). Olanzapine-Induced Depression. Journal of Pharmacy Technology. https://doi.org/10.1177/875512250201800606
389. Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K., Evans, V. D., Fasano, C., & Muir, O. S. (2023). Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview. https://doi.org/10.31234/osf.io/byms6
390. Tak, L. M., & Stevens, A. (2013). [Development of (hypo)mania during discontinuation of venlafaxine in two patients with bipolar disorder].. PubMed.
391. Takahashi, K., Hashimoto, S., Suenaga, T., Nakamura, M., & Kanki, R. (1997). [Kinesigenic supplementary motor seizure? A case report].. PubMed.
392. TAKANASHI, M. (2010). パーキンソン病の非運動症状. Juntendō Igaku/Juntendo igaku. https://doi.org/10.14789/pjmj.56.444
393. Tempelhoff, R., Kofke, W. A., & Dasheiff, R. M. (1997). Anesthetic Implications of Epilepsy, Status Epilepticus, and Epilepsy Surgery. Journal of Neurosurgical Anesthesiology. https://doi.org/10.1097/00008506-199710000-00011
394. Thambirajah, N., Nijam, M. N. S., Vithanawasam, D., Vithanage, K., Liyanage, D. S., Gooneratne, I. K., & Senanayake, S. (2018). Phencyclidine: A rare cause of saccadic intrusions. Annals of Indian Academy of Neurology. https://doi.org/10.4103/aian.aian_174_18
395. Thiel, H.-J., Bayer, A., Zrenner, E., Ried, S., & Schmidt, D. (1991). Early detection of anticonvulsant drug toxicity by colour vision tests. Noninvasive Assessment of the Visual System. https://doi.org/10.1364/navs.1991.md10
396. Todder, D., & Baune, B. T. (2007). Recurrence of suicidal ideation due to treatment with antidepressants in anxiety disorder: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/1752-1947-1-166
397. Tong, T. G. (1975). Phencyclidine Poisoning. JAMA. https://doi.org/10.1001/jama.1975.03260180052023
398. Torre, R. D. L., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., & Camı́, J. (2004). Human Pharmacology of MDMA. Therapeutic Drug Monitoring. https://doi.org/10.1097/00007691-200404000-00009
399. Trujillo, K. A. (2002). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_20
400. Tsuji, Y., Miyama, S., Uemura, Y., Kitanaka, N., Yoneda, A., Mikayama, H., Ohta, Y., Teramura, S., Sawaragi, S., Horikoshi, Y., Yamada, M., Matsu-ura, T., Kitade, H., Mori, T., Okuno, M., Ogura, T., & Takada, H. (2006). [Three cases of drug-induced akathisia due to antiemetics during cancer palliative care].. PubMed.
401. Turki, T. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report. Journal of King Abdulaziz University-Medical Sciences. https://doi.org/10.4197/med.10-1.12
402. Turki, T. A. A., & Arabia, S. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report.
403. Twycross, R. (1975). The use of narcotic analgesics in terminal illness. Journal of Medical Ethics. https://doi.org/10.1136/jme.1.1.10
404. Udangiu, L. N., Roventa, C. E., & Teodorescu, D. (2010). Clinical and Therapeutic Management of Acute Stress Disorder. Management in Health. https://doi.org/10.5233/mih.2010.0013
405. Uddin, M. S., Sufian, M. A., Kabir, M. T., Hossain, M. F., Nasrullah, M., Islam, I., Mamun, A. A., Islam, M. T., & Khanum, S. (2017). Amphetamines: Potent Recreational Drug of Abuse. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.1000330
406. Umapathi, T. (2002). Head drop and camptocormia. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.73.1.1
407. Upadhyaya, S. K., Raval, C., Sharma, D. K., & Vijayvergiya, D. K. (2014). Post-operative Adult Onset Tic Disorder: A Rare Presentation. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.140740
408. Valdez, J. M. (2013). [Status epilepticus in childhood].. PubMed.
409. Valls, J. M. G., Balsalobre, N. R., Perez, A., Limones, P. C., Quintana, Y. S., & Sanchis, N. S. (2007). Respuesta a la TEC en un caso de trastorno explosivo intermitente refractario.. Anales de psiquiatria.
410. Varghese, T., Ahmed, R., Sankaran, J. D., & Al-Khusaiby, S. M. (2002). D-Penicillamine induced myasthenia gravis.. PubMed.
411. Vasquez, E., & Chitwood, W. R. (1975). Postcardiotomy Delirium: An Overview. The International Journal of Psychiatry in Medicine. https://doi.org/10.2190/03fj-9qje-nnbn-b0wc
412. Viladegut, Ó. D. J., Sanya, L. B., Gracia, H. A., & Mayorga, L. O. (2023). Amantadine augmentation in electroconvulsive therapy-resistant catatonia: a case report.. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.2264
413. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
414. Voon, V., Thomsen, T., Miyasaki, J. M., Souza, M. D., Shafro, A., Fox, S. H., Duff‐Canning, S., Lang, A. E., & Zurowski, M. (2007). Factors Associated With Dopaminergic Drug–Related Pathological Gambling in Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneur.64.2.212
415. Vásquez-Dextre, E. R., & Limache-Tueros, M. A. (2015). Acatisia inducida por fármacos no psicotrópicos: a propósito de un caso asociado a metoclopramida.. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.2015.2360
416. Vásquez-Dextre, E. R., & Limache-Tueros, M. A. (2015). Acatisia inducida por fármacos no psicotrópicos: a propósito de un caso asociado a metoclopramida.. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v78i1.2360
417. Waddington, J. L., & Youssef, H. A. (1990). The Lifetime Outcome and Involuntary Movements of Schizophrenia Never Treated with Neuroleptic Drugs. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.156.1.106
418. Wall, G. C., Wasiak, A., & Hicklin, G. A. (2006). An Initially Unsuspected Case of Baclofen Overdose. American Journal of Critical Care. https://doi.org/10.4037/ajcc2006.15.6.611
419. Waller, D. G., Renwick, A., & Hillier, K. (2010). Medical Pharmacology and Therapeutics.
420. Walterscheid, B., Eshak, N., & Nugent, K. (2021). Altered mental status in a patient with psychiatric history: Medication noncompliance or medical etiology?. Journal of Investigative Medicine.
421. Walther, M., & Woods, D. W. (2010). Trichotillomania. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1011
422. Weisdorf, D. J., Kramer, J. A., Goldbarg, A. N., & Klawans, H. L. (1978). Physostigmine for cardiac and neurologic manifestations of phenothiazine poisoning. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt1978246663
423. Wf, B., & Cl, B. (1992). The safety profile of paroxetine.. PubMed.
424. Wheatley, D., Balter, M. B., Levine, J., Lipman, R. S., Bauer, M. L., & Bonato, R. R. (1975). Psychiatric Aspects of Hypertension. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.127.4.327
425. Winters, W. D. (1976). Effects of Drugs on the Electrical Activity of the Brain: Anesthetics. The Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev.pa.16.040176.002213
426. Wroblewski, B., & Joseph, A. B. (1992). The Use of Intramuscular Midazolam for Acute Seizure Cessation or Behavioral Emergencies in Patients With Traumatic Brain Injury. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-199202000-00006
427. Xixis, K. L., Samanta, D., Keenaghan, M., & Vernon, N. T. (2021). Febrile Seizure (Nursing).
428. Yahia, W. B., Thabet, M., Fathallah, N., Guiga, A., Atig, A., Ouni, B., & Ghannouchi, N. (2023). Infliximab-induced depression and Suicidal behaviour: a serious adverse event to consider. Authorea (Authorea). https://doi.org/10.22541/au.169956765.58985984/v1
429. Yoshimura, S., & Imai, K. (1990). PATHOLOGICAL STUDY ON NEUROTOXICITY OF DRUGS. Journal of Toxicologic Pathology. https://doi.org/10.1293/tox.3.65
430. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
431. Zaatreh, M. (2003). Anticonvulsant-induced dyskinesia. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.2.4.385
432. Zaatreh, M. (2003). Anticonvulsant-induced dyskinesia. Expert Opinion on Drug Safety. https://doi.org/10.1517/eods.2.4.385.21421
433. Zagnoni, P., & Albano, C. (2002). Psychostimulants and Epilepsy. Epilepsia. https://doi.org/10.1046/j.1528-1157.2002.043s2028.x
434. Çalıkuşu, C., & Tecer, Ö. (2010). Skin Picking: Clinical Aspects. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511711930.012
435. Çetin, M., & Arıcıoğlu, F. (2013). Unmet needs in psychiatry and emerging novel pharmacological agents. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. https://doi.org/10.5455/bcp.20130927064824
436. Özten, M., & Erol, A. (2013). Fluoxetine Induced Hypomanic Shift in a Bulimic Patient: Case Report. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. https://doi.org/10.5455/bcp.20130112010027